

## Review Article

**Cite this article:** Najdi N, Jung C, Castañeda-Gutiérrez E, Michalski M-C, Beraud V, the French-speaking Pediatric Hepatology, Gastroenterology and Nutrition Group (GFHGNP), Belaïche M, Bouziane-Nedjadi K, Clouzeau H, Coopman S, de l'Hermuzière C, Degas V, Fabre A, Garcette K, Lalanne A, Ley D, Martinez-Vinson C, Piloquet H, Scheers I and Peretti N (2025). Lipid intake in infants from birth to 3 years old: review of current guidelines and knowledge gaps. *Nutrition Research Reviews*, page 1 of 17. doi: [10.1017/S095442242510019X](https://doi.org/10.1017/S095442242510019X)

Received: 18 November 2024

Revised: 4 September 2025

Accepted: 15 September 2025

### Keywords:

Children; Essential fatty acids; Guidelines; Lipid intake; Nutrition

### \*Corresponding author:

Noël Peretti; Email: [noel.peretti@chu-lyon.fr](mailto:noel.peretti@chu-lyon.fr)

© The Author(s), 2025. Published by Cambridge University Press on behalf of The Nutrition Society. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.

# Lipid intake in infants from birth to 3 years old: review of current guidelines and knowledge gaps

Nazek Najdi<sup>1,2</sup>, Camille Jung<sup>3,4,5</sup>, Eurídice Castañeda-Gutiérrez<sup>6</sup>, Marie-Caroline Michalski<sup>1</sup>, Virginie Beraud<sup>6</sup>, the French-speaking Pediatric Hepatology, Gastroenterology and Nutrition Group (GFHGNP), Marc Belaïche<sup>7,8</sup>, Karim Bouziane-Nedjadi<sup>9 10</sup>, Haude Clouzeau<sup>11</sup>, Stéphanie Coopman<sup>12</sup>, Clémentine de l'Hermuzière<sup>1</sup>, Vanessa Degas<sup>13</sup>, Alexandre Fabre<sup>14,15</sup>, Karine Garcette<sup>16</sup>, Arnaud Lalanne<sup>17</sup>, Delphine Ley<sup>12</sup>, Christine Martinez-Vinson<sup>7</sup>, Hugues Piloquet<sup>18</sup>, Isabelle Scheers<sup>19,20</sup> and Noël Peretti<sup>1,2</sup>

<sup>1</sup>Université Claude Bernard Lyon-1, CarMEN laboratory, Pierre Benite, Lyon, France; <sup>2</sup>Hospices Civil de Lyon HCL, Department of Pediatric Gastroenterology-Hepatology and Nutrition, Hôpital Femme Mere Enfant, BRON, France; <sup>3</sup>Centre Hospitalier intercommunal de Créteil, Clinical Research department, Department of pediatrics, Créteil, France; <sup>4</sup>Paris-Est Créteil University, Créteil, France; <sup>5</sup>Groupe Francophone d'Hépatogastro et Nutrition Pédiatrique, Toulouse, France; <sup>6</sup>Health and Happiness Group, H&H Research, Geneva, Switzerland; <sup>7</sup>AP-HP, Hôpital Robert Debré, Département de gastroentérologie et nutrition pédiatrique, Paris, France; <sup>8</sup>Hôpital américain, Service de pédiatrie, Neuilly sur Seine, France; <sup>9</sup>Service de Pédiatrie Amilcar Cabral, CHU Oran, Oran, Algeria; <sup>10</sup>Faculté de Médecine - Université Oran 1 Ahmed Ben Bella, Haï Sabah, Oran, Algeria; <sup>11</sup>CHU Bordeaux, Hôpital des enfants, Groupe Hospitalier Pellegrin, département de gastroentérologie et nutrition pédiatrique, Bordeaux France; <sup>12</sup>Univ. Lille, Inserm, Department of Pediatric Gastroenterology Hepatology and Nutrition, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France; <sup>13</sup>Centre Hospitalier Sud Francilien, Corbeil Essonnes, France; <sup>14</sup>AP-HM, Hôpital La Timone Enfant, Service de pédiatrie multidisciplinaire, Marseille, France; <sup>15</sup>Aix Marseille Univ, Marseille Medical Genetic MMG, Marseille, France; <sup>16</sup>AP-HP, Hôpital Trousseau département de nutrition et gastroentérologie pédiatrique, Paris, France; <sup>17</sup>CHU Lille, Hôpital Jeanne de Flandre, Département de gastroentérologie et nutrition pédiatrique, Lille, France; <sup>18</sup>CHU Nantes, Hôpital enfant-adolescent, Nantes, France; <sup>19</sup>Pediatric Gastroenterology and Hepatology Division, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels 1200, Belgium and <sup>20</sup>Université Catholique de Louvain, Brussels, Belgium

## Abstract

Lipids are essential for child development. Nutritional recommendations are numerous, evolving over time and are often based on expert opinions more than evidence-based medicine. The objective of this review is to critically analyse the evolution of current nutritional recommendations, identify existing knowledge gaps and propose avenues for improvement to optimise infant nutrition and development. A narrative literature review on Pubmed, EMBASE and Cochrane databases (2001–22) was conducted with the keywords: 'alpha-linolenic acid, arachidonic acid, children, cholesterol, docosahexaenoic acid, eicosapentaenoic acid, guidelines, infant, long-chain (LC) PUFA, linoleic acid, lipids and dietary intakes, newborn, palmitic acid and toddler'. Among 861 articles identified, 133 were selected. The main current recommendations are issued by the French Agency for Food Safety (AFSSA), French Agency for Food, Environmental and Occupational Health and Safety (ANSES) and the Food and Agriculture Organization and World Health Organization (FAO-WHO). In infants from 0 to 3 years of age the main challenge is to increase lipid intake while maintaining an optimal omega 6/omega 3 ratio. Current recommendations are focused on polyunsaturated fatty acids, emphasising the intake of linoleic, eicosapentaenoic and docosahexaenoic acids without any specific recommendation for arachidonic acid before the age of 6 months. Points of interest, but without any recommendation, are the incorporation of milk fat, cholesterol, monounsaturated fatty acids, and saturated fatty acids for infants under 6 months. In conclusion, this article identifies knowledge gaps regarding the structural aspect of lipids and the integration of new categories of lipids in future recommendations to promote the quality of infant formulas.

## Introduction

Lipids constitute about 50% of energy intake (EI) in exclusively breast-fed infants. Exclusive breastfeeding for the first 6 months of life has a strong consensus for recommendation<sup>(1,2)</sup>, and human milk is used as a model to define fat and fatty acid (FA) intakes in early life for healthy infants.



Despite breastfeeding promotion campaigns, the rate of breastfeeding initiation remains low in France, which has one of the lowest rates in Europe (around 66%), and has even tended to decline in recent years<sup>(3)</sup>. In addition, to enhance breastfeeding support, it is therefore also important to define as accurately as possible the nutritional framework for infant formulas offered in the absence of breastfeeding.

Recent clinical studies have underlined the essential contribution of fats consumed by children to metabolic programming, and their involvement in the development of neuronal and immune functions in children under 3 years old<sup>(4)</sup>. Thus, infant formulas currently available have a FA profile that more or less faithfully reproduces the natural composition of human milk<sup>(5)</sup>. However, regulations for infant formulas only define a limited number of parameters for lipids<sup>(6,7)</sup> in terms of quantity, while leaving other criteria (such as the addition of arachidonic acid (ARA), and the source of fat, *etc.*) to the discretion of the manufacturer.

Finally, public health messages may appear contradictory to the parents. Indeed, while prevention messages aimed at the lay public advise to reduce fat intake, young children need significantly higher proportions of EI from fat than adults (three to five times higher for children younger than 3 years *v.* adults)<sup>(8,9)</sup>. It is therefore essential to establish clear recommendations to guide parents during the first 1000 days of life. Providing such recommendations is challenging because clinical trials are often not ethically feasible in nutrition, particularly in children, and in the absence of a strong meta-analysis, child nutrition remains a subject of debate among experts.

This literature review aims to provide a comprehensive analysis of current lipid intake recommendations for infants from birth to 3 years of age. By highlighting inconsistencies, contradictions and gaps in existing guidelines, this study seeks to propose evidence-based pathways for enhancing nutritional strategies, particularly in the formulation of infant formulas, to better align with the physiological needs of young children during this critical developmental period.

## Methods

This article is a narrative literature review on the topic of lipid recommendations for young children from birth to 3 years old. This review is based on literature identified through searching PubMed, Embase and Cochrane databases (2001–22) conducted using the keywords: ‘alpha-linolenic acid (ALA), arachidonic acid (ARA), children, cholesterol, docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), guidelines, infant, LC PUFA, linoleic acid (LA), lipids and dietary intakes, newborn, palmitic acid and toddler’.

The selection of relevant literature included articles in English and French and identified 861 articles in the following search engines: Pubmed ( $n = 620$ ), Embase ( $n = 60$ ) and Cochrane ( $n = 181$ ). Articles were excluded if they did not provide the information sought, if they had an insufficient number of cited references ( $<2$ ), if they presented redundant content or were deemed irrelevant or published in a journal of insufficient importance (classified as a ‘predatory journal’, without peer review and low classification rank in the specialty (less than D)).

After deduplication, there were 422 articles left and 104 were withdrawn after reviewing citation eligibility. After removing redundant citations, non-accessible and/or missing sought information, 133 different articles were included (Fig. 1).

## Total lipids

### Definition

Lipids are water-insoluble substances found in plant and animal tissues and are essential for structural and energy needs<sup>(10)</sup>. They exist in various forms, including triacylglycerols, which are the primary nutritional form; fatty acids are an important constituent of many of these lipids including triacylglycerols.

### Energetic function

The body’s physiological needs change with age and require specific nutrient intakes. Indeed, from birth to 3 years, the energy needs derived from total lipids are particularly important, as energy expenditure is high due to rapid growth during this stage of life. In the first months, lipids represent about 35% of weight gain, or 80–90% of the energy value of new tissues<sup>(11)</sup>.

### Current recommendations

Current recommendations on the proportion of EI derived from lipids are not consistent and have varied over the years and between different scientific organisations, with an upward trend in recent years (Table 1).

Currently, the French Agency for Food, Environmental and Occupational Health and Safety (ANSES) recommends 50–55% of EI from lipids in infants under 6 months, which is similar to the lipid content of human breast milk, and then 45–50% for children from 6 months to 3 years of age<sup>(12)</sup>. In fact, epidemiological studies suggest adequate growth as long as lipids are above 30% of the EI<sup>(13)</sup>; below this there is a risk of inadequate intake of energy and fat-soluble vitamins. However, the ANSES recommendation derives from the fact that lipid consumption lower than 50% of total EI (TEI) does not ensure the minimum requirements for certain essential FAs, such as omega 3, and fat-soluble vitamins for infants under 6 months. The 2014 recommendation from the European Food Safety Authority (EFSA) – around 40% for infants aged 6–12 months<sup>(14)</sup> – is very similar to that of ANSES (45%).

## Long-chain polyunsaturated fatty acids (PUFA)


### Generalities

#### Definition

Polyunsaturated fatty acids (PUFA) are fatty acids with at least two double bonds, classified as long-chain when containing more than twelve carbon atoms. Essential PUFA, such as linoleic acid (LA) C18 : 2 (n-6) and alpha-linolenic acid (ALA) C18 : 3 (n-3), cannot be synthesised by the body and must be obtained through diet<sup>(15,16)</sup>. Omega-6 (LA, ARA) and omega-3 (ALA, DHA, EPA) families (Table 2) play critical roles in structural functions, inflammation modulation and neurodevelopment.

#### Metabolism

Endogenous synthesis of DHA and ARA is influenced by the genetic polymorphism of the fatty acids desaturases (FADS) *FADS1* and *FADS2* genes (which encode desaturases 1 and 2, respectively, and limit their synthesis) and by elongases 2/5. Furthermore, the activities of these enzymes depend on the organ (*e.g.* liver, brain, testicle, kidney) in relation to their protein concentration levels and substrate availability<sup>(17)</sup>. The synthesis of PUFA is dependent on various factors, such as diet, nutrients, age, nutritional status and certain pathologies, particularly those

**Table 1.** Evolution of the recommendations on the proportion of energy intake derived from lipids in children aged 0–3 years

| Year           | 2006    |           | 2010   |        | 2011   | 2014   |        | 2016   |
|----------------|---------|-----------|--------|--------|--------|--------|--------|--------|
| Organisation   | FAO-WHO | ESPGHAN   | FAO    | EFSA   | ANSES  | SFP    | EFSA   | ANSES  |
| (Ref.)         | (1)     | (127)     | (43)   | (45)   | (9)    | (13)   | (14)   | (12)   |
| <b>0–6 m</b>   | 40–60%  | 39.6%–54% | 40–60% | –      | 45–50% | –      | 50–55% | 50–55% |
| <b>6–12 m</b>  | –       | –         | 35%    | 40%    | 45–50% | 35–40% | 40%    | 45–50% |
| <b>12–24 m</b> | –       | –         | 35%    | 35–40% | 45–50% | 35–40% | –      | 45–50% |
| <b>24–36 m</b> | –       | –         | 25–35% | 35–40% | 45–50% | 35–40% | –      | 45–50% |

El, energy intake; ANSES, French Agency for Food, Environmental and Occupational Health and Safety; EFSA, European Food Safety Authority; ESPGHAN, European Society of Pediatric Gastroenterology, Hepatology and Nutrition; FAO, Food and Agriculture Organization; m, month; SFP, French Paediatric Society; WHO, World Health Organization.

associated with insulin resistance, as insulin induces the enzymatic activity involved in PUFA synthesis<sup>(18)</sup>. Nutritional intake of DHA and ARA during infancy is important to ensure their availability for growth and development. There is a competition phenomenon between these PUFA since the essential fatty acids (EFA) conversion pathways use the same set of enzymes (desaturases and elongases) for synthesis from their precursors ALA and LA (Fig. 2)<sup>(19)</sup>. A high intake of LA induces excessive synthesis of ARA, which in turn limits DHA and EPA synthesis from ALA, resulting in reduced local availability of long-chain (LC) n-3 PUFA (notably DHA) into membranes. An excessively high LA:ALA ratio in early in life is likely to have negative short- and long-term health effects by reducing cerebral DHA availability and uptake through competition with ALA in the conversion stages<sup>(20)</sup>. In addition, high levels of circulating ARA compete with DHA for incorporation into neuronal membranes. Conversely, high levels of ALA improve the infant's DHA status<sup>(20,21)</sup>. Thus, dietary intake of LA and ALA, and the balance between them, has the potential to affect LC PUFA status, as well as affecting numerous physiological functions such as neuro-cognitive development<sup>(22)</sup>. Moreover, circulating DHA levels depend not only on the ratio of LA to ALA but also on the amount of dietary preformed PUFA supplied<sup>(23)</sup>;

conversely, DHA plays a fundamental role in PUFA synthesis because it downregulates its own liver synthesis by inhibiting EPA elongation<sup>(24,25)</sup>.

### Main functions

EFA, but especially their LC PUFA derivatives, are esterified mainly in the phospholipids of cell membranes, where they have a structural and functional role from fetal life onwards. While PUFA can be used as an energy source, they have numerous physiological roles such as inflammation modulation, immunity and regulation of lipid metabolism, as well as playing an essential role in the functioning of the brain and vision. EFA deficiency impairs lipid and energetic metabolism, cell membrane structures and intracellular signalling pathways. A deep and prolonged deficiency can be detrimental, hence there is dependence on a diet containing both LA and ALA<sup>(22)</sup>.

**Structural and modulation of gene expression.** In the form of phospholipids, these FA are universal constituents of biological membranes: modulating their fluidity and the activity of the proteins they contain (enzymes, receptors and transporters, etc.). They are important for lipid synthesis in physiological barriers

**Table 2.** Main roles of lipids in child development

| Fatty acid family                         | Fatty acid                         | Food sources                                                                                                                | Specific actions                                                                                 |
|-------------------------------------------|------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| <b>Omega-3 (n-3)</b>                      | <b>Alpha-linolenic acid (ALA)</b>  | Flaxseed, rapeseed, walnut oils, chia seeds, walnuts, hemp seeds.                                                           | Precursor for EPA and DHA; anti-inflammatory; supports brain and retinal development             |
|                                           | <b>Eicosapentaenoic acid (EPA)</b> | Fatty fish (e.g. salmon, mackerel, sardines, herring), fish oil, krill oil, shellfish (e.g. mussels, oysters), marine algae | Anti-inflammatory; modulates immune response; supports cardiovascular health                     |
|                                           | <b>Docosahexaenoic acid (DHA)</b>  | Oily fish, algae                                                                                                            | Essential for brain and retinal development; structural role in neuronal membranes               |
| <b>Omega-6 (n-6)</b>                      | <b>Linoleic acid (LA)</b>          | Sunflower, corn, grapeseed, safflower and walnut oil                                                                        | Precursor for ARA; supports cell membrane structure; pro-inflammatory effects                    |
|                                           | <b>Arachidonic acid (ARA)</b>      | Red meat, organ meats, eggs, dairy products, fish, poultry, corn oil                                                        | Structural role in cell membranes; regulates inflammation, immunity, and bone development        |
| <b>Saturated fatty acids (SFA)</b>        | <b>Butyric acid (C4 : 0)</b>       | Dairy products                                                                                                              | Energy source; protects intestinal barrier; modulates cell proliferation                         |
|                                           | <b>Caproic acid (C6 : 0)</b>       | Dairy products, coconut oil                                                                                                 | Rapidly absorbed; energy source for mitochondria                                                 |
|                                           | <b>Lauric acid (C12 : 0)</b>       | Coconut oil, palm oil                                                                                                       | Antimicrobial properties; energy source                                                          |
|                                           | <b>Myristic acid (C14 : 0)</b>     | Dairy products, meat, palm oil                                                                                              | Supports protein acylation; enhances DHA and EPA levels in plasma lipid classes                  |
|                                           | <b>Palmitic acid (C16 : 0)</b>     | Dairy products, palm oil                                                                                                    | Structural role in membranes; energy source; supports protein acylation                          |
| <b>Monounsaturated fatty acids (MUFA)</b> | <b>Oleic acid (C18 : 1 n-9)</b>    | Olive oil, avocados, nuts                                                                                                   | Reduces LDL cholesterol; supports cardiovascular health; energy source                           |
| <b>Trans fatty acids</b>                  | <b>Industrial trans fats</b>       | Processed foods (hydrogenated oils)                                                                                         | Increases LDL cholesterol; reduces HDL cholesterol; associated with cardiovascular risk          |
|                                           | <b>Natural trans fats</b>          | Dairy products, meat                                                                                                        | Less harmful than industrial trans fats; moderate intake may not impair insulin sensitivity      |
| <b>Cholesterol</b>                        | <b>Cholesterol</b>                 | Human milk, eggs, meat, dairy products                                                                                      | Essential for neurological development; regulates cell membrane fluidity; precursor for hormones |

such as the epidermis. They are also involved in the regulation of inflammation through the activation of transcription factors<sup>(26,27)</sup>; it is well documented that n-6 PUFA demonstrate a higher pro-inflammatory effect than the n-3 PUFA.

**Immunity.** FA are precursors of oxygenated mediators that specifically modulate a wide range of cellular functions and can produce multiple effects: haemostasis, platelet aggregation, immune system activity, etc.<sup>(26)</sup>.

A number of clinical studies have shown that LC PUFA can modulate a child's immune status, thereby potentially preventing allergy development. These studies show a positive association between n-6 PUFA levels in breast milk and the risk of developing asthma, while high levels of total n-3 FA are associated with a reduced risk of atopy<sup>(28)</sup>.


The impact of high ARA intake in the evolution or triggering of common childhood inflammatory diseases, such as asthma, eczema, atopic dermatitis and food allergies, is a topic of interest, with ARA intake often inversely related to these allergic diseases<sup>(29,30)</sup>.

**Neurological and ophthalmic.** Furthermore, some LC PUFA are involved from the fetal stage onwards in body growth, central nervous system development and, consequently, cognitive development and retinal function in children<sup>(20,31)</sup>.

Specifically, DHA is central to fetal and infant growth, as well as retinal and visual development. It is a major lipid constituent of photoreceptor membranes, where it plays a crucial role in maintaining their structural and functional integrity<sup>(32)</sup>. It has been shown, for example, that the intake of DHA from algae in infant formulas improves visual acuity in children as young as 12 months<sup>(33)</sup>. This beneficial effect could be explained by the fact that DHA increases mitochondrial activity and has antioxidant, anti-inflammatory, anti-apoptotic and anti-angiogenic effects at the retinal level. Since the continuous renewal of retinal membranes requires a constant supply of n-3 PUFA, DHA-rich diets may even improve retinal function, particularly where damage has already occurred. In particular, DHA is a precursor of oxygenated derivatives, giving it specific properties in the brain such as anti-inflammatory effects and involvement in the apoptosis process<sup>(34)</sup>.

### Importance of PUFA during pregnancy and breastfeeding

Polyunsaturated fatty acids (PUFA), particularly DHA and ARA, are essential during pregnancy and breastfeeding owing to their critical roles in fetal and infant development<sup>(35)</sup>. DHA supports neurodevelopment, visual function and cognitive growth, while ARA contributes to immune function and cellular signalling. Maternal diet significantly influences the PUFA composition of breast milk, as dietary intake of n-3 and n-6 fatty acids directly affects their levels in milk<sup>(36)</sup>. For example, diets rich in DHA, such



**Fig. 2.** Conversion pathways for linoleic and alpha-linolenic acids. The synthesis of omega-6 and omega-3 FA from their respective precursors, the EFA linoleic acid (LA) and alpha-linolenic acid (ALA), is illustrated here. The successive action of desaturases and elongases, which are common to both metabolic pathways, explains the competitive phenomenon that can occur with an excessive intake of one of the EFA.

as those including fatty fish or DHA supplements, enhance DHA levels in breast milk, promoting optimal infant brain and retinal development<sup>(36)</sup>. Conversely, high intake of LA can increase ARA levels but may reduce DHA synthesis due to competition for shared enzymatic pathways<sup>(16)</sup>. Gestational obesity further alters the lipid profile, often increasing n-6 PUFA levels while reducing n-3 PUFA concentrations, which may impact infant health<sup>(37)</sup>. Therefore, balanced maternal dietary intake of n-3 and n-6 PUFA during pregnancy and lactation is crucial for ensuring adequate PUFA transfer to the infant, supporting growth, immune function and long-term health outcomes<sup>(38)</sup>.

### Long-term effect of PUFA intake in children

Preclinical evidence underlines the deleterious short- and long-term role of excess LA, and it has been shown that an increase in dietary intake of LA in Western societies over the last few decades coincides with higher incidences of obesity<sup>(39)</sup> and immune diseases<sup>(40)</sup> at the population level.

Projections for lipid intake from birth to 3 years emphasise the importance of maintaining a balanced lipid profile to support optimal growth and development while mitigating obesity risks. Lipid availability, particularly essential fatty acids such as DHA and ARA, is critical during infancy, as these contribute to neurodevelopment, immune function and metabolic programming<sup>(26)</sup>. Maternal diet during pregnancy and lactation directly influences the lipid composition of breast milk, with high n-6 PUFA intake potentially reducing DHA levels owing to enzymatic competition<sup>(36)</sup>. This imbalance may predispose infants to inflammatory profiles and metabolic dysregulation. Maternal obesity further exacerbates these effects, altering breast milk lipid profiles by increasing n-6 PUFA and saturated fatty acids while reducing n-3 PUFA levels<sup>(41)</sup>. In childhood, excessive lipid intake, particularly from diets high in saturated fatty acids (SFA) and trans fats, can contribute to adiposity and long-term obesity risks<sup>(42)</sup>.

Therefore, ensuring adequate intake of balanced lipids, particularly n-3 PUFA, during early life is essential for preventing obesity and promoting lifelong health.

### Current recommendations

LC PUFA requirements vary from one child to another even within a population of healthy term infants, so the LC PUFA composition of infant formulas is described as a range rather than as a single precise value.

### Essential fatty acids

Table 3 summarises the main official recommendations for EFA intake and their evolution over the past three decades.

The current recommendations' evolution reflects the difficulty of setting a maximum limit for LA intake besides the experimental data available, showing possible adverse effects of high LA intakes as described earlier. Unlike the recommended dietary allowance (RDA) proposed by the French Agency for Food Safety (AFSSA) in 2001<sup>(8)</sup>, the ANSES 2011 report does not give a maximum value for LA and ALA<sup>(9)</sup>. The 2010 the Food and Agriculture Organization and World Health Organization (FAO-WHO) report gives a range for ALA intake between 0.2% and 0.3% EI<sup>(43)</sup>, but no recommendation is given for LA.

Scientific societies and organisations worldwide have mainly specified the minimum physiological requirement for LA in order to limit the imbalance between the two PUFA families when n-3 PUFA consumption is low. In the 1970s, supplementation studies proposed a recommended minimum intake of LA representing 2-7% EI on the basis of the levels observed at that time in human milk. As for ALA, a minimum intake of 0.45% EI is recommended to obtain an optimal DHA status for nerve and visual function<sup>(7)</sup>. These values are currently recommended by ANSES<sup>(12)</sup>, whereas FAO-WHO recommend a slightly lower ALA intake of 0.3% EI<sup>(43)</sup>. It is of importance to note that only the EFSA recommends both lower and upper limits for LA and ALA. Subsequently, the 2016 European regulations (based on EFSA's recommendations) set LA levels at between 500 and 1200 mg/100 kcal and ALA levels at between 50 and 100 mg/100 kcal<sup>(44)</sup>.

EFSA's most recent evolution of EFA RDAs raised the lower limit of LA from 300 to 500 mg/100 kcal and lowered the upper limit of ALA to 100 mg/100 kcal owing to the mandatory addition of DHA to infant formula, thus lowering the required level of its precursor, ALA, in the presence of the preformed dietary DHA provided to adequately cover the physiological needs of infants<sup>(14)</sup>.

Regarding the LA:ALA ratio, the 2006 European directive on infant formulas and follow-on formulas states that it should be between 5 and 15<sup>(44)</sup>. As seen before, this ratio is important for the composition of cell membranes, brain and neurosensory development, and the child's overall health considering the competition phenomenon in EFA conversion pathways. Thus, any imbalance between these two PUFA families could have harmful consequences. However, the rate of conversion of ALA to DHA depends on the absolute amounts of intake of LA and ALA, and not only on their ratio<sup>(13)</sup>. Therefore, this ratio seems to be of less interest today, and the ANSES and FAO-WHO reports in 2010, unlike their predecessors, no longer mention limits for this LA:ALA ratio<sup>(45)</sup>. Nevertheless, this ratio can remain a practical benchmark in the context of overall diet, and remains important in the event of excessive intakes of LA or inadequate intakes of DHA and EPA.

**Table 3.** ALA and LA recommendations for children aged 0–3 years

| Year          | 2001             |              | 2006                 | 2010              | 2011       | 2016                 |
|---------------|------------------|--------------|----------------------|-------------------|------------|----------------------|
| Organisation  | EU               | AFSSA        | EU                   | FAO-WHO           | ANSES      | EU                   |
| Ref.          | (128)            | (8)          | (129)                | (43)              | (9)        | (44)                 |
| <b>LA</b>     |                  |              |                      |                   |            |                      |
| 0–2 d         | >300 mg/100 kcal | 2–4–5% EI    | 300–1200 mg/100 kcal | No recommendation | >2.7 % EI  | 500–1200 mg/100 kcal |
| 1–6 m         |                  |              |                      |                   |            |                      |
| 6 m–3 y       |                  | 2–5% EI      |                      |                   |            |                      |
| <b>ALA</b>    |                  |              |                      |                   |            |                      |
| 0–28 d        | >50 mg/100 kcal  | 0.45–1.5% EI | >50 mg/100 kcal      | 0.2–0.3 % EI      | >0.45 % EI | 50–100 mg/100 kcal   |
| 0–6 m         |                  |              |                      |                   |            |                      |
| 6 m–3 y       |                  | 0.4–1% EI    |                      |                   |            |                      |
| <b>LA/ALA</b> |                  |              |                      |                   |            |                      |
| 0–28 d        | 5–15             | 4–10         | 5–15                 |                   | Optional   |                      |
| 0–6 m         |                  |              |                      |                   |            |                      |
| 6 m–3 y       |                  |              |                      |                   |            |                      |

ALA, alpha-linolenic acid; d, day; EI, energy intake; AFSSA, French Agency for Food Safety; LA, linoleic acid; ANSES, French Agency for Food, Environmental and Occupational Health and Safety; FAO, Food and Agriculture Organization; m, month; WHO, World Health Organization; y, year.

### Long-chain polyunsaturated fatty acids

FAO-WHO and ANSES currently recommend providing pre-formed ARA and DHA for all children aged 0–6 months, *i.e.* 0.5% and 0.32% of total FA for ARA and DHA, respectively (Table 4). These values are based on average values from global surveys of human breast milk<sup>(46)</sup>. For DHA, EFSA's recommendations focus, in particular, on the effect of DHA on children's visual functions: a level of DHA equal to 0.3% of total FA in infant formulas is recommended to ensure good visual development in children<sup>(47)</sup>.

For EFSA, ARA is optional even before 6 months old. As for DHA derived from ALA<sup>(21)</sup>, ARA indispensability, linked to its low formation by conversion of LA, has led to the definition of a minimum physiological requirement of 70 mg/d, ensuring sufficient accumulation of this PUFA in cerebral membranes<sup>(9)</sup>. For infant formulas, this DHA intake should be between 20 and 50 mg/100 kcal, with no specific recommendation for ARA.<sup>(44)</sup>

For EPA, only an EPA/DHA ratio <1 was previously recommended for newborns and infants up to 6 months of age<sup>(9)</sup>, but the current data available is insufficient to define a physiological requirement and a RDA for EPA. Table 4 shows the main changes in LC PUFA recommendations over time for children aged 0–3 years according to various scientific societies and organisations.

### Monounsaturated fatty acids

Monounsaturated fatty acids (MUFA) are FA that have a single unsaturated double bond in their carbon chain. They typically have between sixteen and eighteen carbon atoms in their carbon chain, although variations can exist. In quantitative terms, oleic acid is the major component of MUFA, is actively synthesised by cells and is very abundant in all plant and animal foods. It therefore accounts for almost all the MUFA in human nutrition.

Oleic acid C18 : 1 (n-9) is used as a source of energy and is a constituent of all types of lipids, particularly reserve triacylglycerols (adipose tissue)<sup>(1)</sup>. Increasing the percentage of intake of MUFA,

mainly oleic acid, at the expense of saturated fatty acids (SFAs), leads to a reduction in total cholesterol and LDL-C, without reducing HDL-C in adults<sup>(48)</sup>.

According to the latest ANSES recommendations, the MUFA RDAs are the same for children, adolescents and adults<sup>(9)</sup>. Oleic acid intakes recommended by AFSSA<sup>(9)</sup> are between 15% and 20% TEI. This intake was set at 20% TEI in the agency's official report in 2011<sup>(9)</sup>.

MUFA are constituents of human milk lipids (1.7 g/100 g). To date, there are no specific recommendations on MUFA for infants (0–3 years). The only exception is that European directives recommend a maximum level of erucic acid C22 : 1 (n-9), equal to 1% of total fats for the preparation of infant formulas because of potential adverse effects of this specific minor MUFA<sup>(49,50)</sup>. As MUFA, mainly oleic acid, are very well represented in both the plant and animal world, a varied and balanced diet provides adequate quantities.

### Saturated fatty acids

#### Generalities

SFAs are fully hydrogen-saturated carbon chains, classified by chain length. Different SFA families have very different origins, metabolism and functions, and it is therefore essential to distinguish between them (Table 2). Short-chain SFAs, such as butyric acid, are synthesised by the body and support energy regulation. Medium-chain SFAs, found in coconut oil, are rapidly absorbed independently of chylomicrons and the lymphatic system and are used for energy. Long-chain SFAs, such as palmitic acid, are abundant in the diet and essential for cell membranes and protein acylation (Table 2).

Human milk contains about 2 g of SFA per 100 g milk, and they account for almost half of the total FA content. Palmitic acid is the main SFA in human milk comprising around 25%<sup>(51)</sup>. SFA have several functions in the body. Beyond being a source of energy, they

**Table 4.** ARA and DHA recommendations for children aged 0–3 years

| Year               | 2001  |                   | 2006       | 2010          | 2011      | 2016              |
|--------------------|-------|-------------------|------------|---------------|-----------|-------------------|
| Society            | EU    | AFSSA             | EU         | FAO-OMS       | ANSES     | EU                |
| Reference          | (128) | (8)               | (49)       | (1)           | (9)       | (44)              |
| <b>ARA</b>         |       |                   |            |               |           |                   |
| 0–28 d             |       | 0.1–0.25% EI      | <1% of fat | 0.4–0.6 % TFA | 0.5% TFA  | Optional          |
| 0–6 m              |       |                   |            |               |           |                   |
| 6 m–3 y            |       | No recommendation |            |               | Optional  |                   |
| <b>DHA</b>         |       |                   |            |               |           |                   |
| 0–28 d             |       | 0.1–0.4% EI       |            | 0.2–0.36% TFA | 0.32% TFA | 20–50 mg/100 kcal |
| 0–6 m              |       |                   |            |               |           |                   |
| 6 m–3 y            |       | No recommendation |            |               | 70 mg/j   |                   |
| <b>EPA</b>         |       |                   |            |               |           |                   |
| 0–28 d             |       | 0.05–0.15% EI     |            |               |           |                   |
| 0–6 m              |       |                   |            |               |           |                   |
| 6 m–3 y            |       | No recommendation |            |               |           |                   |
| <b>ARA/DHA</b>     |       |                   |            |               |           |                   |
| 0–28 d             |       |                   |            |               | 1.6       |                   |
| 0–6 m              |       |                   |            |               |           |                   |
| 6 m–3 y            |       |                   |            |               |           |                   |
| <b>EPA/DHA</b>     |       |                   |            |               |           |                   |
| 0–28 d             |       |                   | <1         |               | <1        |                   |
| 0–6 m              |       |                   |            |               |           |                   |
| 6 m–3 y            |       |                   |            |               |           |                   |
| <b>DHA/LC-PUFA</b> |       |                   |            |               |           |                   |
| 0–28 d             |       |                   | <1         |               |           |                   |
| 0–6 m              |       |                   |            |               |           |                   |
| 6 m–3 y            |       |                   |            |               |           |                   |

AFSSA, French Agency for Food Safety; LC PUFA, long-chain polyunsaturated acids; TFA, total fatty acids; ANSES, French Agency for Food, Environmental and Occupational Health and Safety; ARA, arachidonic acid; d, day; DHA, docosahexaenoic acid; EFSA, European Food Safety Authority; EI, energy intake; EPA, eicosapentaenoic acid; FAO, Food and Agriculture Organization; m, month; WHO, World Health Organization; y, year.

are important constituents of membranes<sup>(52)</sup> and needed for the FA acylation of proteins. FA acylation regulates intracellular trafficking, protein–protein and protein–lipid interactions, and each FA confers different biochemical properties. SFAs can also regulate gene transcription via the recruitment of transcription factors<sup>(52,53)</sup>.

#### Short- and long-term effects of a low SFA diet in children

Questions have been raised about the appropriateness of recommending a reduction in SFA intake for children, as excessive restriction could lead to inadequate nutritional intake and subsequently have a negative impact on the child's normal growth and development. However, there was no evidence of adverse effects of reduced SFA intake on anthropometric measures of growth, cognitive development or micronutrient intake in children<sup>(54,55)</sup>. In addition, clinical studies show that diets low in SFA are associated with statistically significant reductions in total and LDL cholesterol and diastolic blood pressure in children and adolescents aged between 2 and 19 years<sup>(56)</sup>.

The Finnish STRIP study assessed the long-term effects of a low-SFA diet started early in infancy. Over a thousand healthy infants were included and randomised at the age of 7 months. At the end of the follow-up, at the age of 10 years, it was shown that current dietary recommendations targeting SFA restriction could be initiated in young children without deleterious consequences for growth, with beneficial effects on atherosclerosis risk factors and arterial function in boys<sup>(57)</sup>.

To our knowledge, there is no specific paediatric study about the deleterious effect of long-chain SFA on cholesterolaemia.

#### Current recommendations

The ANSES and FAO-WHO reports do not include any recommendations on SFA for infants under 6 months of age, even though human milk provides 20–25% of energy in the form of SFA<sup>(54)</sup>. However, for infants and young children aged between 6 months and 3 years, ANSES recommends a total SFA intake of less than 12% TEI and 8% for lauric, myristic and palmitic acids<sup>(9)</sup>. There are no recommended minimum intakes for short- and

medium-chain SFA, which are present in breast milk. Furthermore, the FAO-WHO report recommends a reduction in SFA, without a reduction in lipids, in children aged over 2 years from families with hypercholesterolaemia. Regarding the composition of infant formulas, European regulations impose a maximum level of lauric and myristic acid of 20% of total fats, owing to a possible atherogenic effect, while imposing no restrictions on other SFA such as palmitic acid<sup>(44)</sup>.

## Trans fatty acids

### Generalities

Trans fatty acids (TFAs) have a trans configuration of hydrogen atoms around their double bonds. They can be naturally produced by ruminants or industrially synthesised through hydrogenation. Industrial TFA, found in processed foods, are linked to cardiovascular risks, while natural TFA in dairy and meat are less harmful (Table 2)<sup>(58,59)</sup>.

### Long-term effects of trans fatty acid intake in children

The harmful effects of industrial TFA include an increase in LDL cholesterol and a drop in HDL cholesterol<sup>(60)</sup>. Clinical studies and meta-analyses in adults have shown that an excessive intake of TFA is associated with an increased risk of cardiovascular disease (CVD) in a dose-response manner<sup>(61)</sup>. One study on Spanish children aged 4–5 years old found that the highest quartile of industrial, but not natural, TFA intake was associated with overweight. Another study carried out by Greek researchers on a hundred or so mothers and their 3-month-old infants showed that mothers who consumed at least 4.5 g of TFA per day were almost six times more likely to have a body fat percentage 30% higher. In this case, the risk of the infant having a fat mass greater than 24% is more than doubled. This study showed an association between high consumption of TFA and an increase in body fat in both mother and baby, raising the hypothesis that TFA are an early determinant of obesity<sup>(62)</sup>.

### Current recommendations

In 2005, the ANSES set a maximum intake threshold for total TFA at 2% TEI<sup>(63)</sup> and at 1.5% TEI for TFA of technological industrial origin, whereas the WHO currently recommends limiting their consumption to less than 1% TEI<sup>(64)</sup>, an indication of the increase in the negative effects linked to CVD of this class of lipids in the diet of the general population. For infant formulas and follow-on formulas, the European legislation authorises a maximum level of TFA of 3% of the total fat content to allow milk fat to be used in infant formulas<sup>(49)</sup>.

## Cholesterol

### Generalities

Cholesterol is crucial for neurological development, cell membrane formation and hormone synthesis. It is abundant in human milk ranging between 90 and 150 mg/l (ten times higher than that of vegetable-oil-based formulas and six times higher than that of cow's-milk-based formulas)<sup>(65)</sup>, regulating endogenous cholesterol synthesis in infants. Breast-fed infants have higher cholesterol levels than formula-fed infants, which may positively influence long-term cholesterol metabolism and cardiovascular health (Table 2)<sup>(66)</sup>.

## Long-term effects of a high cholesterol diet in children

### Lipid profile in adulthood

The hypothesis of the long-term impact of a diet rich in cholesterol during childhood emerged in the 1980s with the epigenetic notion that a diet rich in cholesterol early in life could favourably regulate the metabolism of cholesterol and lipoproteins in adulthood<sup>(67,68)</sup>.

Animal studies in baboons suggest that the amount of cholesterol in the diet of the first few months of life (formula or breastfeeding) can affect adult cholesterol metabolism, but in a nonlinear way<sup>(69)</sup>. The potential impact of early life nutrition in CVD incidence has been calculated by the following model: if 30% of infants were exclusively breast-fed, the reduction in endogenous cholesterol synthesis would result in a 0.15 mM drop in adult cholesterol levels, and therefore a reduction in the prevalence of CVD of up to 5% in the population<sup>(70)</sup>.

### Cardiovascular risk

The role of dietary cholesterol in cardiovascular risk is still a matter of debate, and epidemiological or long-term follow-up studies do not allow us to conclude with certainty about the role of early exposure to cholesterol in childhood in relation to cardiovascular risk in adulthood, apart from pathologies such as familial hypercholesterolaemia<sup>(71,72,73)</sup>. In fact, there is no evidence to support its role or lack of effect on cardiovascular risk, as it is not possible to separate its role from that of other nutrients such as TFA, with which it is co-ingested.

Recent epidemiological studies comparing breastfeeding with milk formula show a higher risk of CVD in adulthood in infants fed with infant formulas containing no or low amounts of cholesterol. In a population of 109 young adults who died prematurely and were autopsied, atherosclerosis occurred in 60% of cases in individuals initially fed on artificial milk, compared with 25% of subjects fed on breast milk<sup>(74)</sup>. In another study, it was shown that mortality rates from ischaemic heart disease were higher in a formula-fed population than in a breast-fed population, and that these mortality rates were associated with higher adult total and LDL cholesterol values in the formula-fed population<sup>(70)</sup>. Of note, a major bias in human studies is the comparison of breast-fed newborns versus those fed artificial formula without considering the cholesterol content of the formula and the proportion of breastfeeding, if any, and its duration.

### Current recommendations

Besides the studies published on early exposure of cholesterol impact on long-term cardiovascular risk, to date, there is no recommendation for the addition of cholesterol to infant formula.

## Molecular species carrying FA: glycerolipids, glycerophospholipids, sphingolipids and glycosphingolipids

### Generalities

Even if triacylglycerols (TG) are the main lipids providing dietary FA, breast milk and dairy products also contain many other bioactive lipids such as polar lipids. Their properties depend on the quality of the FA<sup>(75)</sup>.

Polar lipids include mainly glycerophospholipids and sphingolipids. These molecules are amphiphilic, which means they have surface-active properties and can be used as emulsifiers of lipids (TG) in a water medium (micelles), and can auto assemble to form

liposomes or be part of mixed lipid micelles. They have two different parts: a **hydrophilic** 'head' (phosphate group) and a **hydrophobic** 'tail' constituted by two **FA** in glycerophospholipids; the junction between these two parts is a glycerol molecule. They constitute the main part of the cell membranes (cell, mitochondria, endoplasmic reticulum, nucleus, *etc.*) forming lipid bilayers, and they influence the membrane's biophysical properties depending on the composition of their different components (FA unsaturation level, organic molecules attached to the phosphate group, *etc.*). This large family of lipids has also many other roles in cellular signalling, inflammation pathways, neurological transmission and intestinal mucosal integrity among others<sup>(76)</sup>.

Saccharolipids are complex molecules containing FA or a sphingosine branched on a sugar molecule. They are amphipathic and incorporated in cell membranes as the phospholipids. They are involved in a large panel of physiological pathways such as immunological response, cell interaction (apoptosis, tissue repair), brain function and cholesterol regulation<sup>(77)</sup>.

### Current recommendations

To our knowledge, it is of interest to note that there is no formal recommendation about the level of supplementation of glycerophospholipids and sphingolipids in infant formula.

### Discussion: gaps, controversies and paths of improvement for the recommendations on the lipid profile of infant formulas

The evolution of the current recommendations we have just detailed aptly demonstrates the progress in our understanding of the lipid requirements of infants and young children. Maintaining significant calorie intake while achieving an optimal omega 6: omega 3 ratio is at the core of all recommendations put forth by various scientific organisations. The composition of breast milk stands as the gold standard for determining the infant's nutritional intake. Our literature analysis identifies several potential avenues for improvement based on the disparities between the composition of breast milk and the current recommendations regarding the composition of infant and follow-on formulas. These differences can be attributed either to technical difficulties in modifying infant formula or to the lack of studies providing answers to the questions raised.

### Quantitative characterisation of infant formulas' lipid profile

#### Quantitative differences in the lipid profiles of breast milk and infant formulas

Unlike infant formulas, breast milk mainly provides MUFA (45–50%), such as oleic acid (n-9) and palmitoleic acid (n-7), in higher quantities than PUFA (15%), as well as a large proportion of SFA (35–40%) such as palmitic acid and myristic acid (Table 5)<sup>(78)</sup>. However, the precise quantity of MUFA and SFA reported in literature may vary depending on the studies. Indeed, the composition of these FA in milk depends mainly on the nature of the mother's lipid reserves and her dietary intake during pregnancy and lactation. These FA come from both endogenous synthesis and diet<sup>(9)</sup>.

### SFA supplementation

**Palm oil.** The composition of infant formulas aims to be as close as possible to that of breast milk, in which palmitic acid represents about 25% of total FA<sup>(51)</sup>. Palm oil constitutes a widely available

source of palmitic acid, and consumption of formulas with palm oil is associated with an increase in weight-for-length (WLZ) in infants under 6 months, but a decrease in weight-for-age (WAZ) and WLZ in infants aged 6–12 months<sup>(79)</sup>. Because of eco-responsibility, the use of palm oil is a concern for many parents, but currently there is no evidence suggesting that palmitic acid at the levels observed in infant formulas, or the presence of palm oil, have a deleterious effect on child health. Still, current research suggests that other SFA sources, namely, dairy lipids, can be more optimal than palm oil regarding global FA profile and TG structure (mentioned later). There are now infant milks made from other vegetable oils, such as coconut oil<sup>(80)</sup>, but their intensive production may also have an ecological impact and their FA profile is also quite different from human milk, notably the high proportion of C12 in coconut fat.

**Dairy lipids.** Dairy fats are rich in SFA (60–65% of FA including 30% palmitic acid) and low in EFA<sup>(52)</sup>. The varied profile of cow's milk (>400 different FA species) is a richness that vegetable oils lack, including palm oil. This means that infant formula with milk fat provides a greater variety of SFA, and this complex profile is closer to breast milk than can be achieved with vegetable oils alone (Table 5).

Dairy lipids are often considered to be potentially deleterious for CV health in case of excessive intake, as they are rich in SFAs. However, many studies suggest that, when present in a balanced diet, because of the short- and medium-chain SFA and the presence of myristic acid in particular, dairy milk fat optimises cellular and tissue availability of the EFA and LC PUFA. In other words, dairy milk fat's SFA could help the body to synthesise and/or maintain very-long-chain, highly unsaturated FA, particularly those of the omega-3 family such as eicosapentaenoic acid (EPA) and DHA, provided that there is a sufficient intake of the precursor ALA. For example, in primates, compared with a diet low in myristic acid (0.6%), a richer diet containing twice as much myristic acid (1.2%) is associated with an increase in EPA and DHA levels in phospholipids and DHA levels in cholesterol esters<sup>(81)</sup>. This raises the hypothesis that, in humans, a diet with moderate myristic acid intake (1.2% of EI), compared with a lower diet (0.6%), increases DHA and EPA levels in some plasma lipid classes, despite equivalent intake of ALA.

These results suggest that higher dietary SFA of dairy origin contributes at least in part to the maintenance of long-chain n-3 PUFA<sup>(82)</sup>.

At present, regulations do not specify the fat source to be used in infant formulas. It is up to the manufacturer's either to use only vegetable fats, such as palm oil or coconut oil, or to incorporate dairy lipids in the form of milk cream or milk fat.

### LC PUFA supplementation

#### Contains Dot at the End Long-chain polyunsaturated fatty acids..

Intake of LC PUFA in children has been correlated with neurological and immune benefits.

Numerous studies have examined the effect of LC PUFA supplementation on psychomotor and neurosensory development in childhood, particularly in premature infants owing to the increased needs associated with their rapid growth. Better cognitive performance was demonstrated when infant formulas enriched with LC PUFA and milk fat globule membrane (MFGM) were consumed for more than 6 months<sup>(83)</sup>. Paediatric nutritionists agree that it is important for children to receive sufficient and balanced quantities of LC PUFA from the fetal stage and for at least

**Table 5.** Comparison of the nutritional lipid composition of breast milk, cow's milk and infant formulas based on vegetable oils<sup>(46,130,131,108)</sup>

| /100 ml                                      | Breast milk | Cow's milk | Infant formula<br>(with vegetable oils as lipid sources;<br>in this case palm oil and coconut oil) | Infant formula<br>(with dairy products<br>as lipid sources) |
|----------------------------------------------|-------------|------------|----------------------------------------------------------------------------------------------------|-------------------------------------------------------------|
| <b>Fat (g)</b>                               | 3.2–3.6     | 3.6        | 2.6–4                                                                                              | 2.6–4                                                       |
| <b>Triacylglycerols %</b>                    | 98.1–98.8   | 97         | N/A                                                                                                | 98                                                          |
| <b>Phospholipids %</b>                       | 0.26–0.8    | 1.5        | ≤7 ou égal                                                                                         |                                                             |
| <b>Cholesterol (mg/100 ml)</b>               | 9–15        | 1.0–33     | Absent                                                                                             |                                                             |
| <b>Fatty acids as % of total fatty acids</b> |             |            |                                                                                                    |                                                             |
| <b>SFA</b>                                   |             |            |                                                                                                    |                                                             |
| Butyric acid C4 : 0                          | 0.1         | 1.4        | Nq                                                                                                 | 2.4                                                         |
| Caproic acid C6 : 0                          | 0.2         | 2.1        | 0.1                                                                                                | 1.3                                                         |
| Caprylic acid C8 : 0                         | 0.3         | 1.7        | 1.0–1.5                                                                                            | 1.7                                                         |
| Capric acid C10 : 0                          | 2           | 3.5        | 0.9–1.3                                                                                            | 2.2                                                         |
| Lauric acid C12 : 0                          | 6.8         | 3.9        | 7.8–11.5                                                                                           | 6.3                                                         |
| Myristic acid C14 : 0                        | 10.4        | 12.6       | 4.0–5.5                                                                                            | 7.2                                                         |
| Palmitic acid C16 : 0                        | 25          | 29.5       | 18.2–25.4                                                                                          | 18.9                                                        |
| <b>MUFA</b>                                  |             |            |                                                                                                    |                                                             |
| Palmitoleic acid C16 : 1                     | 3.5         | 1.7        | 0.1–0.2                                                                                            | 1.1                                                         |
| Stearic acid C18 : 0                         | 6.9         | 13.3       | 3.5–4.0                                                                                            | 6.7                                                         |
| Oleic acid C18 : 1                           | 33.6        | 26.3       | 28.4–40.8                                                                                          | 28.1                                                        |
| <b>PUFA</b>                                  |             |            |                                                                                                    |                                                             |
| <b>n-6 PUFA</b>                              |             |            |                                                                                                    |                                                             |
| Linoleic acid C18 : 2                        | 17          | 2.9        | 13.3–18.5                                                                                          | 16.7                                                        |
| Arachidonic acid C20 : 4                     | 0.5         |            | Added 0.2–0.6 or not added: nq                                                                     | –                                                           |
| <b>n-3 PUFA</b>                              |             |            |                                                                                                    |                                                             |
| Alpha-linolenic acid C18 : 3                 | 1.7         | 1.1        | 1.6–2.4                                                                                            | 1.5                                                         |
| Docosahexaenoic acid C22 : 6                 | 0.32        |            | Added 0.2–0.3 or not added: nq                                                                     | –                                                           |

MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; SFA, saturated fatty acids; N/A: Not Available; Nq: Not Added.

the first 6 months of their post-natal life, and that any serious deficiency in EFA and LC PUFA could have deleterious and irreversible consequences for the brain, hence the importance of supplementing infant milks and ensuring that the diet of pregnant or breast-feeding women is adequately covered in these FA<sup>(84)</sup>.

Moreover, the antenatal and neonatal periods should be favoured to influence the maturation of the immune system. Supplementing hydrolysates with n-3 PUFA could prevent allergies in at-risk populations<sup>(85)</sup>. Fish oil supplementation during pregnancy leads to an increase in n-3 LC PUFA in breast milk and a decrease in n-6, more markedly than in control mothers. Thus, n-3 PUFA levels are associated with IgA, IL10, IL6 and CD14 levels in breast milk on day 3, which could have a preventive effect on allergy risk<sup>(86)</sup>. The number of studies is still limited and the evidence inconclusive, as such, n-3 PUFA supplementation is not the subject of official recommendations for allergy prevention. Further studies are needed to determine whether n-3 PUFA have an anti-allergy protective effect, and to determine the optimal dose and type of supplementation to ensure this putative anti-allergy effect.

LC PUFA also appear to have an epigenetic programming effect during the period of early ante- and neonatal development in animals and humans<sup>(87)</sup>. Thus, recent studies show that LC PUFA

(DHA such as ARA) could have a long-term effect on children's body growth as they regulate the expression of genes responsible for the development of adipocytes<sup>(22)</sup>.

**ARA and DHA.** To date, the European Commission has made it compulsory to add DHA to infant formula manufactured from February 2020 onwards, but the addition of ARA remains optional<sup>(88)</sup>.

This decision comes from several arguments, mainly that no additional benefit for infants has been demonstrated after the addition of ARA and DHA to formulas. In terms of growth, compared with supplemented formulas, the absence of added ARA and DHA does not alter the growth of infants (weight, height, etc.)<sup>(89)</sup>. In neurological terms, since a large proportion of DHA is found in the cerebral cortex, optimal cerebral development seems to be possible with DHA alone<sup>(90,91)</sup>. It should be remembered that DHA levels increase with age and depend mainly on diet, unlike ARA whose levels depend on age and very little on diet<sup>(92)</sup>. The beneficial effect on visual acuity is only associated with DHA. In fact, supplementation during the first 4 months of life with DHA alone, without ARA, resulted in visual maturation at the age of 4 years, which was identical to that of breast-fed children and superior to that of infants receiving a

formula not enriched with DHA. From this study including sixteen and seventeen children in DHA alone and DHA + ARA supplemented groups, respectively, the use of milk enriched with ARA and DHA seemed not to provide any benefit compared with formula enriched only with DHA.<sup>(93)</sup> It should be noted that according to the Diamond study, DHA intakes higher than the DHA levels measured in breast milk are not associated with additional visual improvement.<sup>(33)</sup>

However, the latest official recommendations from the European Commission and most learned organisations making the addition of ARA to infant formulas optional are the subject of real debate in the field of paediatric nutrition. Several groups of experts suggest that these two LC PUFA should be added simultaneously to infant formulas<sup>(88)</sup>. They support this position because human milk, considered the gold standard in infant nutrition, contains more ARA than DHA<sup>(94)</sup>. In addition, in the absence of adequate dietary intake, endogenous synthesis of ARA is insufficient to ensure the non-neurological biological functions in which it is involved<sup>(95)</sup>. Specifically, genetic variants of desaturases present in 30% of children reduce the endogenous synthesis of ARA<sup>(96)</sup>, so a higher dietary intake of ARA is necessary in carriers of these variants. In fact, the 30% reduction in ARA and EPA is observed in the case of minor alleles of FADS, whereas DHA levels are less affected by this genetic variant than by dietary intake. FADS is a gene that appears to modulate the effect of nutrition on cognition and immune development<sup>(83)</sup>. Miklavcic *et al.* suggest that increasing the supplementation of infant formulas to 34 mg/100 kcal of ARA and 17 mg/100 kcal of DHA prevents the reduction in ARA due to minor alleles<sup>(97)</sup>. Without the addition of ARA, anti-inflammatory and immunosuppressive effects can be obtained and are undesirable in the post-natal period when there is a significant risk of infection.

For all of these reasons, the addition of ARA to infant formulas, in addition to the mandatory addition of DHA, seems desirable. According to the Diamond study, the ARA:DHA ratio in infant formula could influence neurological development, and the respective proportions of ARA and DHA should also be taken into consideration, highlighting an important and relevant effect of the ARA:DHA ratio<sup>(98)</sup>. Similarly, it has been shown that when infants receive both ARA and DHA supplementation, they perform better in terms of cognitive performance than when they receive DHA alone<sup>(99)</sup>. The controversy mainly comes from the heterogeneous results of neurodevelopmental studies on DHA and ARA supplementation. It can be explained by several confounding factors: heterogeneity between studies; a wide variety of judgement criteria and methodological approaches; the impact of genetic variability modulating the rate of endogenous LC PUFA synthesis; the interaction of breastfeeding, which provides preformed LC PUFA; lifestyle; smoking; and socio-economic status<sup>(1)</sup>.

Therefore, the need for high-quality clinical trials is of the utmost importance to answer these questions. The size of the samples chosen is a central parameter for assessing complex intellectual performance, identifying sex differences and the effect of different polymorphisms known to influence FA metabolism. The results of these trials will be important in forming the basis of evidence-based guidelines for LC PUFA formula supplementation for infants and young children.

### Cholesterol supplementation

Human milk contains a higher cholesterol content compared with commercial infant formulas containing only vegetable fats (Table 5). While conclusive evidence from randomised clinical

trials are still lacking, the arguments supporting the addition of cholesterol to infant formula are based on its physiological functions; cholesterol is crucial for neurological development, cell membrane formation and hormone synthesis. Because cholesterol is a key component of the developing brain, its addition to infant formulas may support the growth and functioning of the central nervous system.

A potential impact on lipid metabolism has been suggested by epidemiological studies. Breast-fed infants have higher plasma concentrations of total and LDL cholesterol (LDL-C) than formula-fed infants; however, in the long term, studies have shown lower LDL-cholesterol in individuals who were breast-fed. This difference is attributed to cholesterol in breast milk (15 mg/100 ml), which is absent in infant formula. Oral ingestion of cholesterol early in life may play a part in the hepatic development of lipid degradation enzymes or hepatic receptors for LDL-cholesterol. However, other studies have reported conflicting data regarding the assumed protective effect on cardiovascular level, with similar cholesterol levels after the age of 1 year<sup>(100,101,102)</sup>.

Of note, the addition of cholesterol to infant formulas presents technological and economic challenges that currently limit its widespread implementation. However, the incorporation of milk fat globule membrane (naturally containing cholesterol) in infant formula is a possibility to achieve higher cholesterol content (mentioned later). Although the presence of significant amounts of cholesterol in human breast milk and epidemiological data suggesting its nutritional value, the current lack of recent and rigorous studies makes it challenging to formulate a recommendation on adding cholesterol to infant preparations.


### Qualitative characterization of infant formulas' lipid profiles

#### Triacylglycerol structures

Triacylglycerols (TG) are esters composed of one glycerol and three FA. The main sources of TG are dairy products, vegetable oil and animal fats. Their primary role is energy-related, serving as reserves in adipose tissue and contributing to ATP production.

The position of some FA in the triacylglycerol structure (sn-1 and sn-3 for the outer positions and sn-2 for the central position) can influence their digestion and absorption in the intestine. In this respect, TG structure is different in human, bovine and vegetable fat. Human and bovine milk fat contain a wide variety of FA, whereas vegetable fat variety is poorer and depends on the vegetable species used (blends are used to improve the variety). In human milk, the main TG structures are palmitic acid (C16) at the sn-2 position (see next paragraph) and oleic acid (18 : 1) at the sn-1 or sn-3 position. In bovine milk fat, palmitic acid (C16) at the sn-2 position is also the main TG structure (40–45% of the total amount of palmitic acid is branched at sn-2)<sup>(103)</sup>, with oleic acid (18 : 1) at the sn-1 or sn-3 position<sup>(104)</sup>. Of note, butyrate branches at the sn-3 position and stearic (18 : 0) acid at the sn-1 position. In vegetable fat used for infant formula, palmitic acid at the sn-2 position is less frequent (10–20% only)<sup>(103)</sup>, whereas higher levels of SFA are present at the sn-1 and sn-3 position<sup>(105)</sup> compared with human and bovine milk<sup>(106)</sup>.

**sn-2 palmitate level optimisation.** Palmitic acid (C16) is the most abundant SFA in breast milk, and between 60–70% is esterified at the sn-2 position. During digestion, the action of lipases produces two Non-Esterified Fatty Acids (NEFA) (positions sn-1 and sn-3) and one monoacylglycerol. If palmitic acid is released as NEFA because it was on the sn-1/3 position, it can bind calcium and form



**Fig. 3.** Comparative FA composition and regio-distribution in human milk fat (A) and bovine milk fat (B) (% mol of main FA >0.5 % total). This figure compares human versus bovine milk fat in terms of FA composition (expressed as % mol of main FA >0.5% of total) and also the positional distribution of FA within the triacylglycerol molecule (regio-distribution in the triacylglycerol (TG) core between the external positions sn-1 and sn-3, or the middle position sn-2).

insoluble calcium soaps that are not absorbed and are associated with increased constipation and infant colic<sup>(107)</sup>. Studies have shown a positive correlation between the sn-2 central position of palmitic acid on triacylglycerols and improved digestive comfort in children. This beneficial effect is linked to an increase in the number of *Lactobacillus* and bifidobacteria in the intestine<sup>(105,108)</sup>, and secondly with the lower amount of calcium soaps in faeces, which favours the formation of softer stools<sup>(109,103)</sup>.

Recent studies also show that increasing the level of sn-2 palmitate in infant formula, using milk fat instead of palm oil, is associated with better development of motor skills in children at the age of 16 months, and that the beneficial effects on neuronal development in children are associated with an increase in the level of bifidobacteria in the intestinal microbiota<sup>(110)</sup>.

The optimisation of sn-2 palmitate level in infant milk formulas can be achieved either by industrial restructuring of vegetable fats (palm oil) or the addition of milk fat instead of regular palm oil. This is because in dairy lipids, palmitic acid (C16 : 0) accounts for approximately 25% of total FA and is mostly found in the sn-2 position (Fig. 3). However, despite the importance of the positioning of FA on the TG molecule for FAs bioavailability and the associated benefits on digestion and neuronal development, no recommendation has been formulated so far. Therefore, specific consideration on this point appears necessary for future recommendations.

#### Fat emulsion ultrastructure


**Differences in fat emulsion ultrastructure between breast milk and infant formulas.** In terms of quality, the fat emulsion in human milk and infant formula differs significantly in both structural and biochemical terms.

The fat globules in human breast milk are distinguished from those in infant formula by their larger size and the presence of a phospholipid membrane that modifies intestinal absorption and may confer beneficial properties in terms of body composition and subsequent cardio-metabolic prevention<sup>(111)</sup>. Phospholipids are also essential components of the neurological system and supplementation in animal diet improves brain myelinisation<sup>(112)</sup>. In human clinical studies, supplementation of milk with phospholipids, including sphingomyelin, is associated with

improvement of neurological development, mainly cognitive efficiency<sup>(113)</sup>.

In its native form, women's milk fat is organised into dispersed globules enveloped by a triple phospholipid membrane known as the milk fat globule membrane (MFGM), which originates from the fat-secreting epithelial cells of the mammary gland<sup>(114)</sup>. These MFGM comprise proteins inserted into the phospholipid membrane (mainly at the inner layer), an intermediate layer composed of the phospholipid triple membrane and an outer layer consisting mainly of high-molecular-weight glycoproteins and sphingomyelin/cholesterol complexes (Fig. 4). Milk fat globules have an average diameter of around 3–5 µm, but show a wide size distribution (from 0.1 to 15 µm) in both women's and cow's milk<sup>(115)</sup>. In infant formulas, however, the fat is dispersed as a result of the homogenization of vegetable oils in the presence of milk proteins. This process produces a stable micro-emulsion of plant lipids, mainly stabilised by caseins and potentially added stabilisers such as lecithins, in the form of small lipid droplets, with an average diameter of less than 0.5 µm and no membrane coating (Fig. 4).

**Size of milk fat globule optimisation.** Recent experimental data suggest that the size of milk fat globules is a key parameter in the long-term beneficial effects of breastfeeding, particularly in protecting against metabolic syndrome and obesity<sup>(116)</sup>. During the developmental period in mice, from weaning to young adulthood, consumption of a milk diet composed of large (10 µm) fat globules surrounded by a phospholipid membrane reduced total adipose tissue mass and circulating leptin levels by 25% in adulthood, compared with a diet with a droplet structure characteristic of infant milks<sup>(117)</sup>. This beneficial effect on body composition is also accompanied by an improvement in the animal's metabolic status and, more specifically, insulin sensitivity, with a reduction in the homeostatic model assessment (HOMA) index, fasting glycemia and circulating resistin levels. The authors hypothesise that changes in lipid absorption and digestion kinetics may in turn alter their metabolic utilisation – the balance between catabolism by beta-oxidation and lipogenesis. In rats, the absorption of small fat globules (0.4 µm) formed with adsorbed casein causes a marked reduction in postprandial beta-oxidation of



**Fig. 4.** Structural differences in lipid droplets between breast milk containing native milk fat globules (A) and a microemulsion of plant lipids in infant formula (B). The structural differences between fat in mammalian milk and standard infant formula are presented. Panel A illustrates the structure of the milk fat globule with detailed milk fat globule membrane structure. Panel B, depicting the fat droplet in standard infant formula, highlights differences in terms of size (smaller diameter: 0.3–1  $\mu$ m v. a few nm) and structure (aggregates of protein and emulsifier v. trilayers).

FA compared with large native globules. This difference is thought to result from a delay in the kinetics of triacylglycerol appearance in plasma, linked to slower gastric emptying and lipolysis when small fat globules are ingested<sup>(115,118)</sup>.

Recent studies show that the interfacial coating of breast milk fat globules with MFGM facilitates lipolysis by digestive lipases and bile salts naturally present in breast milk<sup>(114)</sup>. Lipolysis being an interfacial process, gastric and pancreatic lipases hydrolyse fats at the oil–water interface. Thus, the composition and structure of the oil–water interface is likely to affect lipolysis in the gastrointestinal tract. In infants, levels of pancreatic lipase and bile salts are low compared with adults, so the products of gastric lipolysis play an important role in the digestion of milk lipids, compensating for the low levels of pancreatic lipase and emulsifying lipids, respectively. Today's infant formulas contain much smaller thick protein-coated fat droplets than the MFGM-coated fat globules of breast milk. Thus, infant formulas containing bigger fat droplets resulting from MFGM enable a digestion process closer to that of human milk<sup>(111)</sup>.

**Milk fat globule membrane supplementation.** In humans, clinical studies have reported the beneficial effects of MFGM supplementation of infant formulas on neurocognitive development and protection against infectious agents, with no deleterious impact on growth<sup>(119,120)</sup>.

The COGNIS study is a prospective, randomized, double-blind, nutritional intervention study. This study compared seventy children, during their first 18 months of life, fed with either a standard infant formula (SF,  $n = 29$ ) or a bioactive-compound-enriched infant formula (EF,  $n = 41$ ) and thirty-three breast-fed (BF) children (reference group). The results suggest that enriched-infant-formula-fed infants seem to show fewer behavioural problems up to 2.5 years compared with standard-infant-formula-fed infants<sup>(121)</sup>.

In Indonesian infants aged under 8 weeks to 6 months supplemented with MFGM complex lipids, a higher general intelligence quotient (IQ) and better hand–eye coordination and Griffiths scale performance IQ were found at 24 weeks of intervention compared with those fed without MFGM<sup>(122)</sup>.

Another trial in Swedish infants aged 2–6 months supplemented with MFGM (Lacprodan MFGM-10) showed a higher Bayley-III cognitive score at 12 months compared with the unsupplemented group<sup>(123,124)</sup>.

In a Swedish, double-blind, randomized controlled trial including 160 formula-fed healthy term infants and 80 breast-fed reference children, formula supplemented with a protein-rich MFGM concentrate given between 2 and 6 months decreased infectious morbidity until 6 months of age (significantly lower incidence of acute otitis, lower antipyretic use and lower serum concentrations of IgG against *pneumococci* after vaccination)<sup>(119,125)</sup>.

A Franco–Italian study in infants aged 14 d to 4 months, comparing supplementation with either a lipid-rich MFGM fraction (MFGM-L) or MFGM-P (Lacprodan MFGM-10: the first MFGM ingredient to enter the global infant formula market, rich in phospholipids and gangliosides), showed no difference in weight gain for the two groups<sup>(126)</sup>.

The use of MFGM in child nutrition can be provided by specific added products such as buttermilk-based ingredients or directly from milk cream.

These results call into question the historical choice of not including milk fat as part of infant formula and may serve as a basis for new strategies to evolve the nutritional formulations of infant milks. Recently, some formulas have begun to add dairy lipids, whereas the majority of current infant formulas contain lipids of exclusively vegetable origin. This addition of dairy lipids positively impacts both triacylglycerol structure (with increased sn-2 palmitate levels) and fat emulsion composition/ultrastructure with MFGM supplementation. By playing on the complementarity of plant and dairy lipids, rather than eliminating the latter, it seems possible to optimise the composition of infant formulas to make them more similar to breast milk. Preserving dairy lipids would thus have beneficial effects on child development, while retaining interesting taste properties.

## Conclusions

This narrative review highlights the consensus and changes in current recommendations for the lipid intake of young children

under 3 years of age. The contribution of lipids to EI appears to be the most consensual recommendation at the international level. At present, the benefits of a diet rich in omega 3 and 6 are widely recognised in lipid recommendations for young children aged 0–3 years.

However, this work raises persistent questions about current recommendations such as the absence of regulations on the addition of ARA in infant formulas despite clinical evidence showing that concomitant supplementation of ARA and DHA can mimic the effects of breastfeeding and ensure good brain and retinal development in children. It also points out that the evolution of official recommendations mainly concerns the quantitative aspect of LC PUFA while other lipids present in breast milk, such as SFA, MUFA, cholesterol, EPA and the structure of lipids for infants under 6 months, remain without recommendations.

The introduction of milk fat, including sn-2 palmitate and MFGM, seems to be a relevant way to improve the quality of infant formula. However, further randomised controlled trials evaluating the nature and function of lipid matrices are needed to increase scientific knowledge, specifically studies assessing the impact of the structure of lipids ingested during the neonatal period in metabolism programming in adulthood. Recent animal studies have also reported promising results on the supplementation of cholesterol in infant formulas, but the underlying mechanisms still need to be better understood and could help in designing improved nutritional strategies. We are confident that these aspects will lead to future improvements in infant formula and, possibly, to better preventive nutrition for future adults who cannot be initially breast-fed.

**Acknowledgments.** We thank Mrs Claire Bourlieu-Lacanal for providing Fig. 4 and for meaningful dialogue about the article.

**Financial support.** The salary of N. Nazek was funded by Biostime Laboratory during the year of the Master-2.

**Competing interests.** Najdi Nazek has received financial support from Biostime Laboratory for her Master-2 studies. Jung Camille has received grants from: Nestlé, Danone, Menarini and Dairy Goat Co-operative, which are not related to the present literature review. Castañeda-Gutiérrez Euridice is an employee of Health and Happiness Group. Michalski Marie-Caroline received research funding from CNIEL, Sodial-Candia R&I and Danone Nutricia Research; congress travel funding from CNIEL; and symposium honorarium from IMGC, which are not related to the present literature review. Belaïche Marc has received financial support from Danone, Nestlé, Modilac, Reckitt and Biostim, which are not related to the present literature review. Bouziane-Nedjadi Karim declares none. Clouzeau Haude declares none. Coopman Stéphanie received grants from Sanofi, Cell Trion, Mirum and Danone, which are not related to the present literature review. De L'Hermuzière Clémentine declares none. Degas Vanessa declares none. Fabre Alexandre declares none. Garcette Karine has received financial support from Danone, Nutricia, Nestlé, Novalac, Sodilac, Reckitt and Lactalis, which are not related to the present literature review. Lalanne Arnaud declares none. Ley Delphine has received lecture fees from AbbVie and Sandoz, as well as travel grants from Nestlé, all of which are not related to the present literature review. Martinez-Vinson Christine declares none. Piloquet Hugues has received grants from Nestlé, Danone Hipp and Menarini laboratory, which are not related to the present literature review. Scheers Isabelle declares none. Beraud Virginie was an employee of Health and Happiness Group at the moment of her contribution to this review. Peretti Noël has received grants from Lactalis, Nestlé NHS and Nutricia-Danone, which are not related to the present literature review.

**Authorship.** Najdi Nazek: bibliographic research and writing of the first draft. Jung Camille: conception of the article and writing of the article. Castañeda-Gutiérrez Euridice: supervision and correction of the article. Michalski Marie-

Caroline: correction and significant improvement of the article and elaboration of the figures. Bourlieu-Lacanal Claire: correction and significant improvement of the article and elaboration of the figures. Belaïche Marc: correction of the article. Bouziane-Nedjadi Karim: correction of the article. Clouzeau Haude: correction of the article. Coopman Stéphanie: correction of the article. De L'Hermuzière Clémentine: correction of the article. Degas Vanessa: correction of the article. Fabre Alexandre: correction of the article. Garcette Karine: correction of the article. Lalanne Arnaud: correction of the article. Ley Delphine: correction of the article. Martinez-Vinson Christine: correction of the article. Piloquet Hugues: correction of the article. Scheers Isabelle: correction of the article. Beraud Virginie: conception of the article and writing of the article. Peretti Noël: conception, supervision of N. Najdi, writing and significant improvement of the article.

## References

1. FAO WHO. Experts' recommendations on fats and oils in human nutrition1 [Internet]. 1994 [cited 15 July 2024]. Available from: <https://www.fao.org/4/T4660t/t4660t02.htm>
2. WHO Breastfeeding recommendation [Internet]. [cited 8 October 2024]. Available from: [https://www.who.int/health-topics/breastfeeding#tab=tab\\_2](https://www.who.int/health-topics/breastfeeding#tab=tab_2)
3. Guajardo-Villar A, Demiguel V, Smaïli S, Boudet-Berquier J, Pilkington H, Blondel B, et al. (2022) Trends and disparities in breastfeeding initiation in France between 2010 and 2016: results from the French National Perinatal Surveys. *Matern Child Nutr.* **18**, e13410.
4. Nicklaus S (2016) Lipides et comportement alimentaire chez les enfants. *OCL.* **23**, D307.
5. Boué-Vaysse C, Billeaud C, Guesnet P, Couëdelo L, Alessandri JM, Putet G, et al. (2009) Teneurs en acides gras polyinsaturés essentiels du lait maternel en France : évolution du contenu en acides linoléique et alphalinoléique au cours des 10 dernières années. *OCL.* **16**, 4–7.
6. Scientific opinion on the essential composition of infant and follow-on formulae. EFSA J [Internet]. [cited 26 August 2024];(2014;12(7):3760). Available from: <https://data.europa.eu/doi/10.2903/j.efsa.2014.3760>
7. Motarjemi Y (1991) Codex Committee on nutrition and foods for special dietary uses. *Food Control* **2**, 185.
8. Martin A (2001) The “apports nutritionnels conseillés (ANC)” for the French population. *Reprod Nutr Dev.* **41**, 119–28.
9. ANSES A 2010. Actualisation des apports nutritionnels conseillés pour les acides gras. Rapport d'expertise collective. <https://www.anses.fr/fr/system/files/NUT2006sa0359Ra.pdf>. 2011.
10. Entry details | FAO Terminology Portal | Food and Agriculture Organization of the United Nations [Internet]. [cited 26 August 2024]. Available from: <https://www.fao.org/faoterm/viewentry/en/?entryId=178230>
11. Fomon S, Haschke F, Ziegler E, Nelson S (1982) Body composition of reference children from birth to age 10 years. *Am J Clin Nutr* **35**, 1169–75.
12. ANSES. Actualisation des repères du PNNS : élaboration des références nutritionnelles Avis de l'Anses Rapports d'expertise collective. Maisons-Alfort. <https://www.anses.fr/fr/system/files/NUT2012SA0103Ra-2.pdf>. 2016.
13. Briand A, Legrand P, Bocquet A, Girardet JP, Bresson JL, Chouraqui JP, et al. (2014) Lipid intake in children under 3 years of age in France. A position paper by the Committee on Nutrition of the French Society of Paediatrics. *Arch. Pédiatrie* **21**, 424–38.
14. European Food Safety Authority (EFSA) (2017) Dietary reference values for nutrients summary report. *EFSA J* [Internet]. **14**, <https://data.europa.eu/doi/10.2903/sp.efsa.2017.e15121>
15. Carlson SE, Schipper L, Brenna JT, Agostoni C, Calder PC, Forsyth S, et al. (2021) Perspective: moving toward desirable linoleic acid content in infant formula. *Adv Nutr* **12**, 2085–98.
16. Einerhand AWC, Mi W, Haandrikman A, Sheng XY, Calder PC (2023) The impact of linoleic acid on infant health in the absence or presence of DHA in infant formulas. *Nutrients* **15**, 2187.
17. Valenzuela R, Metherel AH, Cisbani G, Smith ME, Chouinard-Watkins R, Klievik BJ, et al. (2024) Protein concentrations and activities of fatty acid desaturase and elongase enzymes in liver, brain, testicle, and kidney from mice: substrate dependency. *BioFactors*. **50**, 89–100.

18. Videla LA, Hernandez-Rodas MC, Metherel AH, Valenzuela R (2022) Influence of the nutritional status and oxidative stress in the desaturation and elongation of n-3 and n-6 polyunsaturated fatty acids: impact on non-alcoholic fatty liver disease. *Prostaglandins Leukot Essent Fat Acids*. **181**, 102441.
19. Sprecher H (1999) An update on the pathways of polyunsaturated fatty acid metabolism. *Current Opin. Clin Nutr Metab. Care*. **2**, 135–8.
20. Simopoulos A (1991) Omega-3 fatty acids in health and disease and in growth and development. *Am J Clin Nutr* **54**, 438–63.
21. Brenna JT (2002) Efficiency of conversion of  $\alpha$ -linolenic acid to long chain n-3 fatty acids in man. *Current Opin. Clin Nutr Metab. Care*. **5**, 127–32.
22. Uauy R, Mena P, Rojas C (2000) Essential fatty acids in early life: structural and functional role. *Proc Nutr Soc*. **59**, 3–15.
23. Lewis E, Steenson S, Haslam RP, McDonald E, Sharman M, Traka M, et al. (2025) Sustainable and available sources of omega-3 fatty acids for health: are the current dietary recommendations, food sources and legislation fit for purpose?. *Nutr Res Rev*. 1–16.
24. Metherel AH, Valenzuela R, Klievik BJ, Cisbani G, Rotarescu RD, Gonzalez-Soto M, et al. (2024) Dietary docosahexaenoic acid (DHA) downregulates liver DHA synthesis by inhibiting eicosapentaenoic acid elongation. *J Lipid Res*. **65**, 100548.
25. Valenzuela R, Metherel AH, Cisbani G, Smith ME, Chouinard-Watkins R, Klievik BJ, et al. (2025) Specific activity of mouse liver desaturases and elongases: time course effects using n-3 and n-6 PUFA substrates and inhibitory responses of delta-6 desaturase. *Biochim Biophys Acta Mol Cell Biol Lipids*. **1870**, 159594.
26. Bazan NG (2007) Omega-3 fatty acids, pro-inflammatory signaling and neuroprotection. *Current Opin. Clin Nutr Metab. Care*. **10**, 136–41.
27. Serhan CN, Arita M, Hong S, Gotlinger K (2004) Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers. *Lipids*. **39**, 1125–32.
28. Soto-Ramírez N, Karmaus W, Zhang H, Liu J, Billings D, Gangur V, et al. (2012) Fatty acids in breast milk associated with asthma-like symptoms and atopy in infancy: a longitudinal study. *J. Asthma*. **49**, 926–34.
29. Miyake Y, Tanaka K, Sasaki S, Arakawa M (2011) Polyunsaturated fatty acid intake and prevalence of eczema and rhinoconjunctivitis in Japanese children: the Ryukyus Child Health Study. *BMC Public Health* **11**, 358.
30. Decsi T, Marosvölgyi T, Muszil E, Bódy B, Szabó É (2022) Long-chain polyunsaturated fatty acid status at birth and development of childhood allergy: a systematic review. *Life (Basel)* **12**, 526.
31. Spector AA (1999) Essentiality of fatty acids. *Lipids* [Internet]. **34**, S1–S3. <https://aocs.onlinelibrary.wiley.com/doi/10.1007/BF02562220>
32. Hadley K, Ryan A, Forsyth S, Gautier S, Salem N (2016) The essentiality of arachidonic acid in infant development. *Nutrients* **8**, 216.
33. Birch EE, Carlson SE, Hoffman DR, Fitzgerald-Gustafson KM, Fu VL, Drover JR, et al. (2010) The DIAMOND (DHA intake and measurement of neural development) study: a double-masked, randomized controlled clinical trial of the maturation of infant visual acuity as a function of the dietary level of docosahexaenoic acid. *Am J Clin Nutr*. **91**, 848–59.
34. Arachidonic Acid and Its Metabolites in Brain (2007) *Glycerophospholipids in the brain*. [Internet]. New York, NY: Springer New York. [http://link.springer.com/10.1007/978-0-387-49931-4\\_5](http://link.springer.com/10.1007/978-0-387-49931-4_5)
35. Muñoz Y, Mercado L, Farias C, Beyer MP, Alvear I, Echeverría F, et al. (2024) Impact of polyunsaturated fatty acids during pregnancy and lactation: a comprehensive review. *Prostaglandins Leukot Essent Fat Acids*. **203**, 102656.
36. Barrera C, Valenzuela R, Chamorro R, Bascuñán K, Sandoval J, Sabag N, et al. (2018) The impact of maternal diet during pregnancy and lactation on the fatty acid composition of erythrocytes and breast milk of Chilean women. *Nutrients* **10**, 839.
37. Gulecoglu Onem MG, Coker C, Baysal K, Altunyurt S, Keskinoglu P (2021) The effects of pre-pregnancy obesity and gestational weight gain on maternal lipid profiles, fatty acids and insulin resistance. *J Perinat Med*. **49**, 873–83.
38. Newberry SJ, Chung M, Booth M, Maglione MA, Tang AM, O'Hanlon CE, et al. (2016) Omega-3 fatty acids and maternal and child health: an updated systematic review. *Evid Rep Technol Assess (Full Rep)*. 1–826.
39. Innis SM (2011) Metabolic programming of long-term outcomes due to fatty acid nutrition in early life. *Matern Child Nutr* **7**, 112–23.
40. Prescott SL & Dunstan JA (2007) Prenatal fatty acid status and immune development: the pathways and the evidence. *Lipids*. **42**, 801.
41. Álvarez D, Muñoz Y, Ortiz M, Maliqueo M, Chouinard-Watkins R, Valenzuela R (2020) Impact of maternal obesity on the metabolism and bioavailability of polyunsaturated fatty acids during pregnancy and breastfeeding. *Nutrients* **13**, 19.
42. Malin Igra A, Ekström S, Andersson N, Ljungman P, Melén E, Kull I, et al. (2025) Biomarkers of dietary PUFA intake in childhood and adolescence in relation to cardiometabolic risk factors in young adulthood: a prospective cohort study in Sweden. *Am J Clin Nutr*. **121**, 558–66.
43. Organisation des Nations Unies pour l'alimentation et l'agriculture, Organisation mondiale de la santé, editors. Fats and fatty acids in human nutrition: report of an expert consultation 10–14 November 2008, Geneva. Rome: FAO; 2010. (FAO food and nutrition paper).
44. Delegated regulation - 2016/127 - EN - EUR-Lex [Internet]. [cited 15 July 2024]. Available from: [https://eur-lex.europa.eu/eli/reg\\_del/2016/127/oj](https://eur-lex.europa.eu/eli/reg_del/2016/127/oj)
45. EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA). Scientific opinion on dietary reference values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol. EFS2 [Internet]. 2010 Mar [cited 2024 Jul 15];8(3). Available from: <https://data.europa.eu/doi/10.2903/j.efsa.2010.1461>
46. Brenna JT, Varamini B, Jensen RG, Diersen-Schade DA, Boettcher JA, Arterburn LM (2007) Docosahexaenoic and arachidonic acid concentrations in human breast milk worldwide. *Am J Clin Nutr* **85**, 1457–64.
47. Carlson SE & Colombo J (2016) Docosahexaenoic acid and arachidonic acid nutrition in early development. *Advances Pediatrics* **63**, 453–71.
48. Kris-Etherton PM, Pearson TA, Wan Y, Hargrove RL, Moriarty K, Fishell V, et al. (1999) High-monounsaturated fatty acid diets lower both plasma cholesterol and triacylglycerol concentrations. *Am J Clin Nutr* **70**, 1009–15.
49. Directive 2006/141/CE de la Commission du 22 décembre 2006 concernant les préparations pour nourrissons et les préparations de suite et modifiant la directive 1999/21/CE Texte présentant de l'intérêt pour l'EEE [Internet]. OJ L Dec 22, 2006. Available from: <http://data.europa.eu/eli/dir/2006/141/oj/fra>
50. Directive - 2006/125 - EN - EUR-Lex [Internet]. [cited 2024 Jul 15]. Available from: <https://eur-lex.europa.eu/eli/dir/2006/125/oj>
51. Koletzko B (2016) Human milk lipids. *Ann Nutr Metab*. **69**, 27–40.
52. Legrand P (2008) Intérêt nutritionnel des principaux acides gras des lipides du lait. *Chole-Doc CERIN* [Internet]. [https://www.cerin.org/wp-content/uploads/2008/01/105-interet-nutritionnel-principaux-acides-gras-lipides-lait-choledoc\\_01.pdf](https://www.cerin.org/wp-content/uploads/2008/01/105-interet-nutritionnel-principaux-acides-gras-lipides-lait-choledoc_01.pdf)
53. Legrand P & Rioux V (2015) Specific roles of saturated fatty acids: beyond epidemiological data. *Euro J Lipid Sci. Tech*. **117**, 1489–99.
54. Lifshitz F & Moses N (1989) Growth failure. A complication of dietary treatment of hypercholesterolemia. *Am J Dis Child*. **143**, 537–42.
55. Kaplan RM & Toshima MT (1992) Does a reduced fat diet cause retardation in child growth?. *Prev Med* **21**, 33–52.
56. Te Morenga L & Montez JM (2017) Health effects of saturated and trans-fatty acid intake in children and adolescents: systematic review and meta-analysis. *PLoS One* **12**, e0186672.
57. Hakanen M, Lagström H, Kaitosaari T, Niinikoski H, Nantö-Salonen K, Jokinen E, et al. (2006) Development of overweight in an atherosclerosis prevention trial starting in early childhood. The STRIP study. *Int J Obes*. **30**, 618–26.
58. Tardy AL, Lambert-Porcheron S, Malpuech-Brugère C, Giraudet C, Rigaudière JP, Laillet B, et al. (2009) Dairy and industrial sources of trans fat do not impair peripheral insulin sensitivity in overweight women. *Am J Clin Nutr*. **90**, 88–94.
59. Tardy AL, Morio B, Chardigny JM, Malpuech-Brugère C (2011) Ruminant and industrial sources of trans-fat and cardiovascular and diabetic diseases. *Nutr Res Rev*. **24**, 111–7.
60. Brouwer IA, Wanders AJ, Katan MB (2010) Effect of animal and industrial trans fatty acids on HDL and LDL cholesterol levels in humans – a quantitative review. *PLoS ONE* **5**, e9434.

61. Zhu Y, Bo Y, Liu Y (2019) Dietary total fat, fatty acids intake, and risk of cardiovascular disease: a dose-response meta-analysis of cohort studies. *Lipids Health Dis.* **18**, 91.
62. Anderson AK, McDougald DM, Steiner-Asiedu M (2010) Dietary trans fatty acid intake and maternal and infant adiposity. *Eur J Clin Nutr.* **64**, 1308–15.
63. ANSES. Risques et bénéfices pour la santé des acides gras trans apportés par les aliments. Recommandations ANSES [Internet]. 2005. Available from: <file:///C:/Users/perettino/Desktop/Biblio/besoins%20nutritionnels/ANSES%20recommandations%20apports%20AG%20trans%20NUT-Ra-AGtrans.pdf>
64. Plus de 3 milliards de personnes protégées contre les acides gras trans nocifs dans leur alimentation [Internet]. [cited 18 July 2024]. Available from: <https://www.who.int/fr/news/item/09-09-2020-more-than-3-billion-people-protected-from-harmful-trans-fat-in-their-food>
65. Wu D, Zhang L, Zhang Y, Shi J, Tan CP, Zheng Z, et al. (2023) Lipid profiles of human milk and infant formulas: a comparative lipidomics study. *Foods* **12**, 600.
66. Nakada S, Ho FK, Celis-Morales C, Pell JP (2023) Association between being breastfed and cardiovascular disease: a population cohort study of 320 249 participants. *J. Public Health* **45**, 569–76.
67. Reiser R & Sidelman Z (1972) Control of serum cholesterol homeostasis by cholesterol in the milk of the suckling rat. *J Nutr.* **102**, 1009–16.
68. O'Brien BC, Pullarkat R, Darsie J, Reiser R (1979) Delayed responses in rats and mice to early postnatal diets. *J Nutr.* **109**, 989–98.
69. Mott GE, Jackson EM, McMahan CA, McGill HC (1990) Cholesterol metabolism in adult baboons is influenced by infant diet. *J Nutr.* **120**, 243–51.
70. Fall CH, Barker DJ, Osmond C, Winter PD, Clark PM, Hales CN (1992) Relation of infant feeding to adult serum cholesterol concentration and death from ischaemic heart disease. *BMJ.* **304**, 801–5.
71. Kratz M (2005) Dietary cholesterol, atherosclerosis and coronary heart disease. *Handb Exp Pharmacol.* 195–213.
72. Spence JD, Jenkins DJA, Davignon J (2010) Dietary cholesterol and egg yolks: not for patients at risk of vascular disease. *Can J Cardiol.* **26**, e336–339.
73. Lecerf JM & De Lorgeril M (2011) Dietary cholesterol: from physiology to cardiovascular risk. *Br J Nutr.* **106**, 6–14.
74. Martin RM & Davey Smith G (2009) Does having been breastfed in infancy influence lipid profile in later life?: a review of the literature. *Adv Exp Med Biol.* **646**, 41–50.
75. Osawa T, Fujikawa K, Shimamoto K (2024) Structures, functions, and syntheses of glycerophospholipids. *Front Chem.* **12**, 1353688.
76. Feingold KR Introduction to Lipids and Lipoproteins. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000 [cited 2024 Oct 7]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK305896/>
77. Park J, Choi J, Kim DD, Lee S, Lee B, Lee Y, et al. (2021) Bioactive lipids and their derivatives in biomedical applications. *Biomol Ther (Seoul).* **29**, 465–82.
78. Grote V, Verduci E, Scaglioni S, Vecchi F, Contarini G, Giovannini M, et al. (2016) Breast milk composition and infant nutrient intakes during the first 12 months of life. *Eur J Clin Nutr.* **70**, 250–6.
79. Young B (2020) Variation in infant formula macronutrient ingredients is associated with infant anthropometrics. *Nutrients* **12**, 3465.
80. Our world in data. Our World in Data. 2021 [cited 15 July 2024]. Oil palm production. Available from: <https://ourworldindata.org/grapher/palm-oil-production>
81. Dabadie H, Peuchant E, Bernard M, LeRuyet P, Mendy F (2005) Moderate intake of myristic acid in sn-2 position has beneficial lipidic effects and enhances DHA of cholesteryl esters in an interventional study. *J Nutr Biochem.* **16**, 375–82.
82. Rioux V & Legrand P Matière grasse laitière et biodisponibilité des acides gras polyinsaturés. [Internet]. Chole-Doc, CERIN; 2013. Available from: <file:///C:/Users/perettino/Desktop/Biblio/besoins%20nutritionnels/Mati%C3%A8re%20grasse%20laiti%C3%A8re%20et%20biodisponibilit%C3%A9%20des%20acides%20gras%20polyinsatur%C3%A9s.%20Rioux%20V,%20Legrand%20P.%20CERIN.pdf>
83. Salas Lorenzo I, Chisaguano Tonato AM, De La Garza Puentes A, Nieto A, Herrmann F, Dieguez E, et al. (2019) The effect of an infant formula supplemented with AA and DHA on fatty acid levels of infants with different FADS genotypes: the COGNIS study. *Nutrients* **11**, 602.
84. Crawford M (1993) The role of essential fatty acids in neural development: implications for perinatal nutrition. *Am J Clin Nutr.* **57**, 703S–710S.
85. Vandenplas Y, Meyer R, Chouraqui JP, Dupont C, Fiocchi A, Salvatore S, et al. (2021) The role of milk feeds and other dietary supplementary interventions in preventing allergic disease in infants: fact or fiction?. *Clin Nutr.* **40**, 358–71.
86. Denburg JA, Hatfield HM, Cyr MM, Hayes L, Holt PG, Sehmi R, et al. (2005) Fish oil supplementation in pregnancy modifies neonatal progenitors at birth in infants at risk of atopy. *Pediatr Res.* **57**, 276–81.
87. Lepping RJ, Honea RA, Martin LE, Liao K, Choi I, Lee P, et al. (2019) Long-chain polyunsaturated fatty acid supplementation in the first year of life affects brain function, structure, and metabolism at age nine years. *Dev. Psychobiol.* **61**, 5–16.
88. Koletzko B, Bergmann K, Brenna JT, Calder PC, Campoy C, Clandinin MT, et al. (2020) Should formula for infants provide arachidonic acid along with DHA? A position paper of the European Academy of Paediatrics and the Child Health Foundation. *Am J Clin Nutr.* **111**, 10–6.
89. Jasani B, Simmer K, Patole SK, Rao SC (2017) Long chain polyunsaturated fatty acid supplementation in infants born at term. *cochrane database syst rev.* [internet]. 3. <http://doi.wiley.com/10.1002/14651858.CD000376.pub4>
90. Birch EE, Hoffman DR, Uauy R, Birch DG, Prestidge C (1998) Visual acuity and the essentiality of docosahexaenoic acid and arachidonic acid in the diet of term infants. *Pediatr Res.* **44**, 201–9.
91. Tounian P, Bellaïche M, Legrand P (2021) ARA or no ARA in infant formulae, that is the question. *Arch Pediatr.* **28**, 69–74.
92. Makrides M, Neumann M, Byard R, Simmer K, Gibson R (1994) Fatty acid composition of brain, retina, and erythrocytes in breast- and formula-fed infants. *Am J Clin Nutr.* **60**, 189–94.
93. Birch EE, Garfield S, Castañeda Y, Hughbanks-Wheaton D, Uauy R, Hoffman D (2007) Visual acuity and cognitive outcomes at 4 years of age in a double-blind, randomized trial of long-chain polyunsaturated fatty acid-supplemented infant formula. *Early Hum. Dev.* **83**, 279–84.
94. Fu Y, Liu X, Zhou B, Jiang AC, Chai L (2016) An updated review of worldwide levels of docosahexaenoic and arachidonic acid in human breast milk by region. *Public Health Nutr.* **19**, 2675–87.
95. Lien EL, Richard C, Hoffman DR (2018) DHA and ARA addition to infant formula: current status and future research directions. *Prostaglandins, Leukotrienes Essent. Fat Acids* **128**, 26–40.
96. Lattka E, Klopp N, Demmelmair H, Klingler M, Heinrich J, Koletzko B (2012) Genetic variations in polyunsaturated fatty acid metabolism – implications for child health?. *Ann Nutr Metab.* **60**, 8–17.
97. Miklavcic JJ, Larsen BMK, Mazurak VC, Scalabrini DMF, MacDonald IM, Shoemaker GK, et al. (2017) Reduction of arachidonate is associated with increase in B-cell activation marker in infants: a randomized trial. *J Pediatr Gastroenterol Nutr.* **64**, 446–53.
98. Colombo J, Carlson SE, Cheatham CL, Shaddy DJ, Kerling EH, Thodousoff JM, et al. (2013) Long-term effects of LCPUFA supplementation on childhood cognitive outcomes. *Am J Clin Nutr.* **98**, 403–12.
99. Liao K, McCandliss BD, Carlson SE, Colombo J, Shaddy DJ, Kerling EH, et al. (2017) Event-related potential differences in children supplemented with long-chain polyunsaturated fatty acids during infancy. *Dev. Sci.* **20**, e12455.
100. Friedman G & Goldberg S (1975) Concurrent and subsequent serum cholesterol of breast- and formula-fed infants. *Am J Clin Nutr.* **28**, 42–5.
101. Huttunen J, Saarinen U, Kostiaainen E, Siimes M (1983) Fat composition of the infant diet does not influence subsequent serum lipid levels in man. *Atherosclerosis* **46**, 87–94.
102. Bayley TM, Alasmi M, Thorkelson T, Jones PJH, Corcoran J, Krug-Wispe S, et al. (2002) Longer term effects of early dietary cholesterol level on synthesis and circulating cholesterol concentrations in human infants. *Metabolism* **51**, 25–33.

103. Mehrotra V, Sehgal SK, Bangale NR (2019) Fat structure and composition in human milk and infant formulas: implications in infant health. *Clin Epidemiol Glob Health*. **7**, 153–9.
104. Bourlieu C & Michalski MC (2015) Structure–function relationship of the milk fat globule. *Current Opin. Clin Nutr Metab. Care*. **18**, 118–27.
105. Miles EA & Calder PC (2017) The influence of the position of palmitate in infant formula triacylglycerols on health outcomes. *Nutr Res*. **44**, 1–8.
106. Tu A, Ma Q, Bai H, Du Z (2017) A comparative study of triacylglycerol composition in Chinese human milk within different lactation stages and imported infant formula by SFC coupled with Q-TOF-MS. *Food Chem*. **221**, 555–67.
107. Innis SM (2011) Dietary triacylglycerol structure and its role in infant nutrition. *Adv Nutr*. **2**, 275–83.
108. Hageman JHJ, Danielsen M, Nieuwenhuizen AG, Feitsma AL, Dalsgaard TK (2019) Comparison of bovine milk fat and vegetable fat for infant formula: implications for infant health. *Int. Dairy J*. **92**, 37–49.
109. Bar-Yoseph F & Lifshitz Y, Cohen T (2013) Review of sn-2 palmitate oil implications for infant health. *Prostaglandins Leukot Essent Fat Acids*. **89**, 139–43.
110. Wu W, Zhao A, Liu B, Ye WH, Su HW, Li J, *et al.* (2021) Neurodevelopmental outcomes and gut bifidobacteria in term infants fed an infant formula containing high sn-2 palmitate: a cluster randomized clinical trial. *Nutrients* **13**, 693.
111. Gallier S, Vocking K, Post JA, Van De Heijning B, Acton D, Van Der Beek EM, *et al.* (2015) A novel infant milk formula concept: mimicking the human milk fat globule structure. *Colloids Surf B Biointerfaces*. **136**, 329–39.
112. Oshida K, Shimizu T, Takase M, Tamura Y, Shimizu T, Yamashiro Y (2003) Effects of dietary sphingomyelin on central nervous system myelination in developing rats. *Pediatr Res*. **53**, 589–93.
113. Tanaka K, Hosozawa M, Kudo N, Yoshikawa N, Hisata K, Shoji H, *et al.* (2013) The pilot study: sphingomyelin-fortified milk has a positive association with the neurobehavioural development of very low birth weight infants during infancy, randomized control trial. *Brain Dev*. **35**, 45–52.
114. Bourlieu C, Deglaire A, Oliveira SC de, Ménard O, Gouar YL, Carrière F, *et al.* (2017) Towards infant formula biomimetic of human milk structure and digestive behaviour. *OCL*. **24**, D206.
115. Michalski MC, Briard V, Michel F, Tasson F, Poulain P (2005) Size distribution of fat globules in human colostrum, breast milk, and infant formula. *J Dairy Sci*. **88**, 1927–40.
116. Brink LR & Lönnerdal B (2020) Milk fat globule membrane: the role of its various components in infant health and development. *J Nutr Biochem*. **85**, 108465.
117. Oosting A, Kegler D, Wopereis HJ, Teller IC, van de Heijning BJM, Verkade HJ, *et al.* (2012) Size and phospholipid coating of lipid droplets in the diet of young mice modify body fat accumulation in adulthood. *Pediatr Res*. **72**, 362–9.
118. Borel P, Armand M, Pasquier B, Senft M, Dutot G, Melin C, *et al.* (1994) Digestion and absorption of tube-feeding emulsions with different droplet sizes and compositions in the rat. *JPN J Parenter Enteral Nutr*. **18**, 534–43.
119. Timby N, Domellöf M, Lönnerdal B, Hernell O (2017) Supplementation of infant formula with Bovine milk fat globule membranes. *Adv Nutr*. **8**, 351–5.
120. Hernell O, Timby N, Domellöf M, Lönnerdal B (2016) Clinical benefits of milk fat globule membranes for infants and children. *J. Pediatr*. **173**, S60–5.
121. Nieto-Ruiz A, Diéguez E, Sepúlveda-Valbuena N, Herrmann F, Cerdó T, López-Torrecillas F, *et al.* (2020) The effects of an infant formula enriched with milk fat globule membrane, long-chain polyunsaturated fatty acids and synbiotics on child behavior up to 2.5 years old: the COGNIS study. *Nutrients* **12**, 3825.
122. Gurnida DA, Rowan AM, Idjradinata P, Muchtadi D, Sekarwana N (2012) Association of complex lipids containing gangliosides with cognitive development of 6-month-old infants. *Early Hum. Dev*. **88**, 595–601.
123. Timby N, Domellöf E, Hernell O, Lönnerdal B, Domellöf M (2014) Neurodevelopment, nutrition, and growth until 12 mo of age in infants fed a low-energy, low-protein formula supplemented with bovine milk fat globule membranes: a randomized controlled trial. *Am J Clin Nutr*. **99**, 860–8.
124. Timby N, Lönnerdal B, Hernell O, Domellöf M (2014) Cardiovascular risk markers until 12 mo of age in infants fed a formula supplemented with bovine milk fat globule membranes. *Pediatr Res*. **76**, 394–400.
125. Timby N, Hernell O, Vaarala O, Melin M, Lönnerdal B, Domellöf M (2015) Infections in infants fed formula supplemented with bovine milk fat globule membranes. *J Pediatr Gastroenterol Nutr*. **60**, 384–9.
126. Billeaud C, Puccio G, Saliba E, Guillois B, Vaysse C, Pecquet S, *et al.* (2014) Safety and tolerance evaluation of milk fat globule membrane-enriched infant formulas: a randomized controlled multicenter non-inferiority trial in healthy term infants. *Clin Med Insights Pediatr*. **8**, 51–60.
127. Koletzko B, Baker S, Cleghorn G, Neto UF, Gopalan S, Hernell O, *et al.* (2005) Global standard for the composition of infant formula: recommendations of an ESPGHAN coordinated international expert group. *J Pediatr Gastroenterol Nutr*. **41**, 584–99.
128. Commission Directive 96/4/EC, Euratom of 16 February 1996 amending Directive 91/321/EEC on infant formulae and follow-on formulae (Text with EEA relevance) [Internet]. OJ L 16 February 1996. Available from: <http://data.europa.eu/eli/dir/1996/4/oj/eng>
129. Commission Directive 2006/125/EC of 5 December 2006 on processed cereal-based foods and baby foods for infants and young children (Codified version) (Text with EEA relevance) [Internet]. OJ L 5 December 2006. Available from: <http://data.europa.eu/eli/dir/2006/125/oj/eng>
130. Ballard O & Morrow AL (2013) Human milk composition. *Pediatr Clin North America*. **60**, 49–74.
131. Delplanque B, Gibson R, Koletzko B, Lapillonne A, Strandvik B (2015) Lipid quality in infant nutrition: current knowledge and future opportunities. *J Pediatr Gastroenterol Nutr*. **61**, 8–17.